North American Association of Central Cancer Registries, Inc. (NAACCR)

2016 Implementation Guidelines and Recommendations

(For NAACCR Standards Volume II, Data Standards and Data Dictionary, Version 16, effective with cases diagnosed on or after January 1, 2016)

Version 1.5

November 2015
Revised December 2015
Revised January 2016
Revised March 2016
Revised June 2016
# Table of Contents

1. **Introduction** .................................................................................................................. 1
2. **New Data Items** .............................................................................................................. 1
3. **Changed Data Items** ........................................................................................................ 2
   3.1 **Record Layout Changes** ............................................................................................ 2
   3.2 **Addition of Clinical and Pathologic Indicators to AJCC T, N, and M** ...................... 3
   3.3 **Sex [220]** .................................................................................................................. 3
   3.4 **Census Ind Code 2010 [272] and Census Occ Code 2010 [282]** .............................. 3
   3.5 **TNM Path Staged By [930] and TNM Clin Staged By [990]** ................................. 3
   3.6 **Wording changes to accommodate EHR reporting** ................................................. 4
   3.7 **SEER Coding Sys-Current and Original [2120 and 2130]** .................................... 4
4. **Other Changes** ............................................................................................................... 4
   4.1 **Staging Transition** ..................................................................................................... 4
   4.2 **Addition of Clinical and Pathologic indicators to AJCC T, N, and M Values** .......... 5
      4.2.1 **TNM Classification Designator Impact for Central Registries** .......................... 6
   4.3 **ICD-O-3 Histologies** ................................................................................................. 6
      4.3.1 **New Terms and Codes Not Yet Implemented** ............................................... 6
      4.3.2 **Newly Reportable Conditions** ......................................................................... 6
5. **EDITS** ............................................................................................................................ 6
6. **Standard Setters Reporting Requirements for 2016** ..................................................... 7
   6.1 **CoC Reporting Requirements** .................................................................................... 7
   6.2 **CDC NPCR Reporting Requirements** ...................................................................... 9
   6.3 **NCI SEER Reporting Requirements** ....................................................................... 14
   6.4 **CCCR Reporting Requirements** ............................................................................. 15
7. **Summary for Central Cancer Registries** .......................................................................... 16
   7.1 **Record Length, New Data Items, and Changed Data Items** .................................. 16
      7.1.1 **Record Length** .................................................................................................. 16
      7.1.2 **New Data Items** .............................................................................................. 16
      7.1.3 **Changed Data Items** ....................................................................................... 16
   7.2 **Staging Transition** ..................................................................................................... 16
   7.3 **ICD-O-3 Histologies** ................................................................................................. 16
   7.4 **Central Registry Edits** .............................................................................................. 17
   7.5 **Software Implementation Plan** ................................................................................ 17
2016 Implementation Guidelines Task Force

Peggy Adamo, BS, AAS, RHIT, CTR
NCI SEER
Email: adamom@mail.nih.gov

Amy Kahn, MS, CTR
New York State Cancer Registry
Email: amy.kahn@health.ny.gov

Kim Best
Rocky Mountain Cancer Data System
Email: kim.best@utah.edu

Jenna Mazreku, CTR
California Cancer Registry
Email: jmazreku@ccr.ca.gov

Castine Clerkin
CDC NPCR
Email: hhe2@cdc.gov

Linda Mulvihill, CTR
NCRA Representative
Email: epe9.lgm@gmail.com

Dan Curran, MS, CTR
C/NET Solutions
Email: danc@askcnet.org

Winny Roshala, BA, CTR
Cancer Registry of Greater California
Email: wroshala@crgc-cancer.org

Leona Douglas, CHIM, CTR
Saskatchewan Cancer Agency
Email: Leona.douglas@saskcancer.ca

Suzanne Schwartz, MS, CTR
New Jersey State Cancer Registry
Email: Suzanne.schwartz@doh.state.nj.us

Lori Havener, CTR
NAACCR
Email: lhavener@naaccr.org

Kathleen Thoburn, BA, CTR
ACoS CoC
Email: kthoburn@facs.org

Annette Hurlbut, RHIT, CTR
Elekta
Email: Annette.hurlbut@elekta.com
1 Introduction

The North American Association of Central Cancer Registries, Inc. (NAACCR), has been working with the American College of Surgeons (ACoS) Commission on Cancer (CoC), National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) Program, Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR), Canadian Council of Cancer Registries (CCCR), central cancer registries, and cancer registry software vendors to develop an implementation plan for NAACCR Standards for Cancer Registries Volume I: Data Standards and Data Dictionary Version 16 (Standards Volume II, Version 16). The 2016 data standards have been developed in response to requested revisions from a broad set of constituents. Data Transmission standards should be consistently maintained among all hospital and central cancer registries and should be implemented in a planned and timely manner. Changes to the set of standards have potential consequences, and implementation must be evaluated by each program, central cancer registry, software vendor, and reporting facility during the planning process. Delays in implementation may result in inconsistent data collection.

Effective with Standards Volume II, Version 16, there are several new geocoding data items. Most significantly, there are numerous changes and many new data items associated with the transition from the Collaborative Stage System to collection of directly-assigned staging components. Since requirements associated with the staging component data items vary by standard setter, it is important for all users of this document to be knowledgeable regarding the distinctions. Most of these changes, including all definitions of the new items and modifications in the column assignments are specified in Version 16: http://www.naaccr.org/StandardsandRegistryOperations/VolumeII.aspx.

2 New Data Items

Four new County at DX Geocode data items [94-97] were introduced in order to identify an address’s geocode relative to each given decennial census. This is necessary because for some states and counties there have been changes to county boundaries, and therefore county of some particular addresses, over time. Appropriate county-census tract combinations are important for deriving census-related socioeconomic factors, such as poverty indicators.

The RuralUrban Continuum 2013 [3312] captures the population size and degree of urbanization by county to aide researchers when investigating how proximity to metropolitan areas and urbanization correlate to the burden of cancer. This data item is derived electronically and should not be entered by an abstractor.

The data items listed below have been introduced as part of the staging transition and data collection requirements that vary among standard setters (see section 6 for more details):

- Six Mets at DX data items [1112-1117]
- Three Tumor Size data items [752-754]
- Eleven derived TNM data items [3605, 3610, 3614, 1616, 1618, 3620, 3622, 3624, 3626, 3650, 3655]
Standards Volume II, Version 16
New Data Items

<table>
<thead>
<tr>
<th>Data Item Name</th>
<th>Item #</th>
<th>Column</th>
<th>Source of Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>County at DX Geocode 1990</td>
<td>94</td>
<td>464-466</td>
<td>NAACCR</td>
</tr>
<tr>
<td>County at DX Geocode 2000</td>
<td>95</td>
<td>467-469</td>
<td>NAACCR</td>
</tr>
<tr>
<td>County at DX Geocode 2010</td>
<td>96</td>
<td>470-472</td>
<td>NAACCR</td>
</tr>
<tr>
<td>County at DX Geocode 2020</td>
<td>97</td>
<td>473-475</td>
<td>NAACCR</td>
</tr>
<tr>
<td>RuralUrban Continuum 2013</td>
<td>3312</td>
<td>476-477</td>
<td>NAACCR</td>
</tr>
<tr>
<td>Mets at DX-Bone</td>
<td>1112</td>
<td>838-838</td>
<td>SEER</td>
</tr>
<tr>
<td>Mets at DX-Brain</td>
<td>1113</td>
<td>839-839</td>
<td>SEER</td>
</tr>
<tr>
<td>Mets at DX-Distant LN</td>
<td>1114</td>
<td>840-840</td>
<td>SEER</td>
</tr>
<tr>
<td>Mets at DX-Liver</td>
<td>1115</td>
<td>841-841</td>
<td>SEER</td>
</tr>
<tr>
<td>Mets at DX-Lung</td>
<td>1116</td>
<td>842-842</td>
<td>SEER</td>
</tr>
<tr>
<td>Mets at DX-Other</td>
<td>1117</td>
<td>843-843</td>
<td>SEER</td>
</tr>
<tr>
<td>Tumor Size Clinical</td>
<td>752</td>
<td>844-846</td>
<td>SEER</td>
</tr>
<tr>
<td>Tumor Size Pathologic</td>
<td>754</td>
<td>847-849</td>
<td>SEER</td>
</tr>
<tr>
<td>Tumor Size Summary</td>
<td>756</td>
<td>850-852</td>
<td>SEER/CoC</td>
</tr>
<tr>
<td>Derived SEER Path Stg Grp</td>
<td>3605</td>
<td>853-857</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Clin Stg Grp</td>
<td>3610</td>
<td>858-862</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Cmb Stg Grp</td>
<td>3614</td>
<td>863-867</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Combined T</td>
<td>3616</td>
<td>868-872</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Combined N</td>
<td>3618</td>
<td>873-877</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Combined M</td>
<td>3620</td>
<td>878-882</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Cmb T Src</td>
<td>3622</td>
<td>883-883</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Cmb N Src</td>
<td>3624</td>
<td>884-884</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SEER Cmb M Src</td>
<td>3626</td>
<td>885-885</td>
<td>SEER</td>
</tr>
<tr>
<td>SEER Primary Tumor*</td>
<td>772</td>
<td>886-888</td>
<td>SEER</td>
</tr>
<tr>
<td>SEER Regional Nodes*</td>
<td>774</td>
<td>889-891</td>
<td>SEER</td>
</tr>
<tr>
<td>SEER Mets*</td>
<td>776</td>
<td>892-893</td>
<td>SEER</td>
</tr>
<tr>
<td>Derived SS2017*</td>
<td>762</td>
<td>894-894</td>
<td>SEER</td>
</tr>
<tr>
<td>Directly Assigned SS2017*</td>
<td>764</td>
<td>895-895</td>
<td>SEER</td>
</tr>
<tr>
<td>NPCR Derived Clin Stg Grp</td>
<td>3650</td>
<td>896-899</td>
<td>NPCR</td>
</tr>
<tr>
<td>NPCR Derived Path Stg Grp</td>
<td>3655</td>
<td>900-903</td>
<td>NPCR</td>
</tr>
</tbody>
</table>

*These new data items will not be collected for 2016.

3 Changed Data Items

3.1 Record Layout Changes

The overall record layout remains the same length. Column spaces for some of the data items have been moved in the record layout in order to accommodate the new data items and expanded length of the TNM Clin Staged By and TNM Path Staged By data items, see section 3.5.

In the Demographic section the length of Reserved 02 changed to 50 characters to accommodate the addition of the new data items County at DX Geocode 1990, 2000, 2010 and 2020 and the RuralUrban Continuum 2013.
In the Hospital Specific section, the length of Reserved 04 changed to 30 characters to accommodate the new staging data items and the relocation of TNM Path Staged By and TNM Clin Staged By to the beginning of the Stage/Prognostic Factors section. Reserved 19 and Reserved 20 were added to the layout where the TNM Staged By data items were previously located.

3.2 Addition of Clinical and Pathologic Indicators to AJCC T, N, and M
Clinical and pathologic indicators are being added to six of the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. The indicators are to be added by modifying the existing values for the individual T, N, and M data items. The revisions will be incorporated into software look ups to allow for selection of necessary ‘p’ values within the clinical codes and selection of necessary ‘c’ values within the pathologic codes when abstracting. See section 4.2 and Appendix C for complete details.

3.3 Sex [220]
The word hermaphrodite formerly classified under code 3 in Sex is an outdated term. The definition was updated to code 3 Other (intersex, disorders of sexual development/DSD).

3.4 Census Ind Code 2010 [272] and Census Occ Code 2010 [282]
The Census Ind Code 2010 and Census Occ Code 2010 were renamed to Census Ind Code 2010 CDC and Census Occ Code 2010 CDC. “Blank” has been added as an allowable value for both data items when coding has not been attempted. Alternative names were added for each field, along with revisions to the Description, Rationale, and Coding Instruction to clarify that the field uses NIOSH non-paid worker codes in addition to U.S. Census Bureau codes to improve consistency of data for research use.

3.5 TNM Path Staged By [930] and TNM Clin Staged By [990]
The length of both Staged By data items has been expanded to 2 digits to accommodate new codes.

Refer to the most recent version of FORDS for additional coding instructions. See Appendix A for the conversion crosswalk from the 1 character codes to the expanded 2 character codes.

Codes
00 Not staged
10 Physician, NOS, or physician type not specified in codes 11-15
11 Surgeon
12 Radiation Oncologist
13 Medical Oncologist
14 Pathologist
15 Multiple Physicians; tumor board, etc.
20 Cancer registrar
30 Cancer registrar and physician
40 Nurse, physician assistant, or other non-physician medical staff
50 Staging assigned at another facility
60 Staging by Central Registry
88 Case is not eligible for staging
99 Staged but unknown who assigned stage
3.6 Wording changes to accommodate EHR reporting
The data items listed in Appendix B were updated to harmonize Standards Volume II, Version 16 with data coming in from electronic health record (EHR) reporting. For example, in the description and/or rationale for many of these data items, reference to “hospital” was replaced with “reporting facility”.

3.7 SEER Coding Sys-Current and Original [2120 and 2130]
Code G was added for the use of the 2016 SEER Coding Manual.

4 Other Changes

4.1 Staging Transition
This section provides a brief summary of the staging transition efforts. See section 6, Standard Setters Reporting Requirements for 2016, for detailed information and requirements.

The Collaborative Stage Transition Newsletter provides communications from the standard setters regarding the transition from Collaborative Stage. The following is a link to the newsletters: http://seer.cancer.gov/registrars/cs-tnm/.

CCCR: Canada will continue to use the Collaborative Stage Data Collection System Version 02.05 to stage their new cases until the end of the 2016 diagnosis year.

CoC: The CoC’s transition away from use of Collaborative Stage includes the requirement of AJCC clinical and pathologic stage (enforced via edits), SEER Summary Stage 2000, and new Tumor Size Summary and Mets at Diagnosis data items. The CoC will continue to use the Collaborative Stage Data Collection System Version 02.05 for cases diagnosed 2004-2015, and only for the collection of Site-specific Factors (SSF) for cases diagnosed 1/1/2016 and forward. The CoC has made no changes to their SSF requirements. In addition to the SSFs, Regional Nodes Positive and Examined and Lymph-vascular Invasion will continue to be required. All other CS input data items are no longer required.

CDC NPCR: Effective with cases diagnosed in 2016, CDC requires directly-assigned SEER Summary Stage 2000 and AJCC TNM 7th Edition Clinical and Pathologic Stage in lieu of CSv2. The Collaborative Stage Data Collection System Version 02.05 will continue to be used for cases diagnosed 2004-2015 and for the collection of the Site-Specific Factors (SSFs) for cases diagnosed 1/1/2016 and forward. In addition to the SSFs, Regional Nodes Positive and Examined and Lymph-vascular Invasion will continue to be required. All other CS input data items are no longer required.

NCI SEER: All SEER registries will submit directly-assigned clinical and pathologic TNM 7th Edition T, N, M and either directly-assigned stage group values or stage group values assigned by the SEER software. Approximately one half of SEER registries will continue the collection of CS v.02.05 for cases diagnosed 1/1/2016 and forward. Those registries will use the CS algorithm to calculate the SEER Summary Stage 2000 and the Derived AJCC TNM 7th Edition values (in addition to coding the directly-assigned fields). SEER registries not collecting CS will submit the directly-assigned SEER Summary Stage 2000. All SEER registries will continue to collect the required CSv2 SSFs. In addition to the SSFs, Regional Nodes Positive and Examined and Lymph-vascular Invasion will continue to be required. The Collaborative Stage Data Collection System Version 02.05 will continue to be used for cases diagnosed 2004-2015.
4.2 Addition of Clinical and Pathologic indicators to AJCC T, N, and M Values

The primary considerations when assigning AJCC staging classifications are timeframe and criteria. The clinical staging (or classification) timeframe includes information obtained from the time of diagnosis throughout the diagnostic workup and ends at the initiation of definitive treatment. Within the clinical staging timeframe, criteria include physical exam, imaging, endoscopies, and diagnostic biopsies. It is important to emphasize that the mere existence of a pathology report that includes microscopic assessment does not exclude it from the clinical staging criteria. If the assessment was a part of the diagnostic workup, it has occurred within the clinical timeframe and can be used for clinical staging.

The pathologic staging/classification timeframe includes information obtained from the moment of diagnosis and throughout the diagnostic workup (i.e., all information from clinical classification), the operative findings and pathology report from the definitive surgery. Within the pathologic staging timeframe, criteria include all of the clinical staging criteria, operative findings from the surgeon, and the pathology report for the resected specimen. Observations from the surgeon in the operative findings that are not accompanied by a biopsy are included in the pathologic staging criteria (e.g., observation of extension without a tissue sample for pathologic review). Similarly, involvement found on imaging is considered in the pathologic staging criteria even in the absence of tissue biopsy.

According to the AJCC manual and trainings, the appropriate T, N, and M categories should be assigned based on the above AJCC rules. This may entail allowing, for example, the pathologic staging M category to be properly assigned as cM1. However, cancer registry abstracting software is currently set up to code two separate and mutually exclusive clinical and pathologic strings of T, N, M, and stage categories, with an implied “c” in the clinical TNM string, and an implied “p” in the pathologic TNM string. Upon abstraction, the registrar has no way of recording the appropriate M category for the pathologic stage if it is cM1. This discrepancy between registry software data items and AJCC staging classification rules causes a dilemma for registrars when abstracting the T, N, and M data items and results in inconsistent coding practices and data loss.

Consequently, as part of the transition away from Collaborative Stage towards directly-assigned TNM stage, all of the standard setting organizations have agreed to address this issue by adding clinical and pathologic indicators to the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. The indicators will be incorporated by adding the prefixes of “c” and “p” to existing valid clinical and pathologic T, N, and M codes respectively, modifying a few of the existing codes for the individual T, N, and M data items, as well as adding and deleting specific existing codes newly prefixed with a ‘c’ or ‘p’ (for example, addition of c0, c1, c1A, c1B, c1C, c1D, and c1E to the list of valid values for pathologic M data item). In addition, in some cases conversion of historical data will be required (see section 6 for standard setter-specific conversion requirements).

This will allow for selection of necessary ‘p’ values within the clinical string and selection of necessary ‘c’ values within the pathologic string within NAACCR Version 16-compliant abstraction software (See Appendix C for a complete listing of valid values for each of the 6 individual data items). The benefits of this implementation will reduce coding confusion and increase registrar confidence in coding AJCC stage, decrease data compromise and loss and increase data integrity, and reduce the time and resources registrars and standard setters currently spend addressing these issues. AJCC will be providing trainings to reinforce the proper abstraction of clinical and pathologic T, N, and M data items and assignment of AJCC stage. See FORDS Revised for 2016 for valid values and instructions for coding.
4.2.1 TNM Classification Designator Impact for Central Registries

With the implementation of the TNM c and p classification designators (TNM c and p ‘prefixes’ or ‘indicators’), central registries will need to consider how to best operationalize receiving directly-assigned pre-2016 TNM data from reporting facilities. This includes issues and options central registries should consider for receiving both converted and non-converted directly-assigned pre-2016 TNM data. A NAACCR Task Force was developed to identify and itemize the issues and options central registries should consider. The NAACCR Task Force findings are included in Appendix H.

4.3 ICD-O-3 Histologies

4.3.1 New Terms and Codes Not Yet Implemented

The NAACCR Guidelines for ICD-O-3 Update Implementation (published December 2013) included a table of new ICD-O-3 codes and terms effective for 2015; however, the use of the new codes was postponed due to issues with adding these codes to the CSv2 software. For diagnosis year 2016, all standard setters have agreed to postpone these codes once again, and to use the alternate codes published in Table 2 of the NAACCR Guidelines for ICD-O-3 Update Implementation (Appendix D). It is anticipated that these codes will be implemented in 2017 when the AJCC-TNM 8th Edition goes into effect.

Hospital registrars should look for use, by their pathologists, of the terms included in Appendix D. Since these terms have not yet been officially adopted for cancer surveillance in North America, registrars should abstract cases using the acceptable codes listed in Appendix D to report them to central registries and to CoC.

4.3.2 Newly Reportable Conditions

SEER implemented reporting of additional terms and codes as newly reportable over the course of 2014 and 2015. CDC and CoC are adding some or all of these terms to their respective reportability lists for cases diagnosed January 1, 2016 and later. See section 6 for the changed reporting requirements specific to each of the Standard Setters.

5 EDITS

The Standards Volume II, Version 16 metafile includes new edits for the new and modified data items as specified in Standards Volume II, Version 16. The edits and edit sets are consistent with the reporting requirements as specified in this document by CoC, NPCR, SEER, and CCCR. Of particular note are many new TNM edits.

The Version 16 metafile was released June 20, 2016, and will be available to download from the NAACCR Web site: [http://www.naaccr.org/StandardsandRegistryOperations/VolumeIV.aspx](http://www.naaccr.org/StandardsandRegistryOperations/VolumeIV.aspx). As additional changes are made to the metafile, NAACCR Listserv messages will be sent out to the cancer registry community.

Hospital registries preparing a submission for NCDB should download their metafile from [https://www.facs.org/quality-programs/cancer/ncdb/datasub/edits](https://www.facs.org/quality-programs/cancer/ncdb/datasub/edits)

Of note are the additional 4 new edit sets. Three of the edit sets are for use only by central registries and are related to the TNM Classification Designators. See Appendix H for additional information. The 4th new edit set is for use by hospital registries that are required to continue to collect all CS data items. This edit set differs from the standard CoC hospital edit set in that it allows all CS values to be collected whereas the
standard CoC hospital edit sets forces all non-required CS data items to be blank. See section 6 for additional information on CS reporting requirements. The four new edits sets are listed below:

- Pre2016 no c, p in codes
- Pre2016 c, p required
- Pre2016 c, p mixed bag
- Hosp: Vs16 COC Required - All + CS

It should also be noted that changes that were made to the NAACCR v15A metafile, will be carried over into the v16 metafile. These changes will have no effect on edits results and will not be noticeable to the end users of the edits. However, users of the EditWriter software need to be aware of these changes as they generate their v16 edits metafiles in particular when importing between metafiles. To accommodate future versions of the EditWriter software (currently under development), all binary tables have been replaced with DBF tables.

Contact Jim Hofferkamp at jhofferkamp@naaccr.org with any questions or concerns about the v16 NAACCR metafile.

6 Standard Setters Reporting Requirements for 2016

6.1 CoC Reporting Requirements

For all cases diagnosed on or after January 1, 2016, the Commission on Cancer (CoC) will require its accredited programs to use Facility Oncology Registry Data Standards (FORDS): Revised for 2016; Collaborative Stage Data Collection System Version 02.05 for the collection of Site-specific Factors only; continued use of 7th Edition of the AJCC Cancer Staging Manual; the most current multiple primary and histology rules; the Hematopoietic rules; and, the SEER*RX systemic therapy application.

Revisions to CoC reporting requirements for 2016 are minimal and are primarily due to the discontinued use of Collaborative Stage to stage cancer cases. Other than the below-specified revisions, CoC data reporting requirements remain the same (including requirement of CS Site-Specific Factors):

**Newly-reportable Conditions/Tumors:**

1. Non-invasive mucinous cystic neoplasm of the pancreas with high-grade dysplasia replaces mucinous cystadenocarcinoma, non-invasive (8470/2).
2. Solid pseudopapillary neoplasm of pancreas (8452/3) is synonymous with solid pseudopapillary carcinoma (C25._).  
3. Cystic pancreatic endocrine neoplasm (CPEN). Assign 8150/3 unless specified as a neuroendocrine tumor, Grade 1 (8240/3) or neuroendocrine tumor, Grade 2 (8249/3).
4. Mature teratoma of the testes in adults is malignant (assign 9080/3), but continues to be non-reportable in prepubescent children (9080/0). Report only if pubescence is explicitly stated in the medical record. Do not report if there is no mention of pubescence in the medical record.

**Data Items No Longer Required (Required historically for cases diagnosed 2004-2015):**

- CS Tumor Size [2800]
- CS Extension [2810]
- CS Tumor Size/Ext Eval [2820]
- CS Lymph Nodes [2830]
CS Lymph Nodes Eval [2840]
CS Mets at DX Data Items [2850-2854]
CS Mets Eval [2860]
CS Version Derived [2936]
Derived AJCC-6 Data Items [2940-3000]
Derived SS and Flag Data Items [3010-3050]
Derived AJCC-7 Data Items [3400-3430]

**Specific Data Items with Continuing Requirement (Required for cases diagnosed 2004+):**
Regional Nodes Positive [820]
Regional Nodes Examined [830]
Lymph-vascular Invasion [1182]
CS Site-specific Factors [2861-2880, 2890-2930]
CS Version Input Original [2935]
CS Version Input Current [2937]

**Note:** CoC’s requirements for the Site-specific Factors have **not changed from 2015**; the data items of CS Version Input Original and Current continue to be required to accommodate continued collection of the SSFs.

**Newly-required Data Items (Required for cases diagnosed 2016+):**
Tumor Size Summary [756]
SEER Summary Stage 2000 [759]
New Mets at DX Data Items [1112-1117]

**Implementation of Clinical and Pathologic Indicators for the AJCC T, N, and M Data Items**
CoC will require CoC-Approved Cancer Programs to add clinical and pathologic indicators to the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900] and convert historical data upon upgrading to NAACCR version 16-compliant software. See Appendix C for a listing of look-up value tables that will be implemented in CoC-accredited hospitals for cases of all diagnosis years abstracted using NAACCR version 16-compliant software.

See Appendix C for conversion specifications for historical data. Conversion of historical data for the diagnosis years of 2015 and earlier is being carried out for the purposes of formatting the data to accommodate consistent viewing, abstraction and editing of the data across all diagnosis years. As a result, it is important to avoid inferring, by data analysis, presentation, or other methods, any meaning to the “c” and “p” prefixes for cases diagnosed in 2015 and earlier. The indicators are only intended to reflect clinical significance for cases diagnosed January 1, 2016 and later, and should not be analyzed in any fashion for cases diagnosed earlier.

**Requirement of Clinical and Pathologic AJCC Stage Enforced by Edits**
Beginning with cases diagnosed January 1, 2016 and later, both clinical and pathologic AJCC stage will be required for data submission to the NCDB. Requirement will be enforced via edits.
No Submission of Derived Stage to the NCDB for Cases Diagnosed 2016 and Later
For cases diagnosed 2016 and later, no software-derived values should be submitted in the directly-assigned AJCC Stage data items [910, 970]. Registrars are encouraged to fully understand how their vendor software functions, and should never manually copy over any derived values.

Documenting Clinical and Pathologic AJCC Stage
Physicians are responsible for documenting physician-assigned clinical and pathologic stage in the patient medical record. Hospital registrars are responsible for recording the physician-assigned stage in the registry database. HOWEVER,

a. If the stage assigned by the physician is inconsistent with the documentation in the medical record, the registrar should assign the stage and record the registrar-assigned stage in the registry database. The registrar should verify the case information with the physician, as he or she may have additional information that would aid in the assignment of a stage. However, it is outside the realm of the responsibility of the registrar to educate the physician. The registrar should inform the registry physician advisor and refer identified coding issues to the Cancer Committee for quality improvement activities.

b. If no physician-assigned stage can be found in the medical record, the registrar should assign the stage and record it in the registry database. The registrar should inform the registry physician advisor and refer identified documentation issues to the Cancer Committee for quality improvement activities.

CoC Cancer Program Standard 1.10, Clinical Educational Activity, states that the required cancer-related educational activity offered to physicians, nurses, and other allied health professionals is to be focused on the use of AJCC (or other appropriate) staging. The cancer committee is encouraged to use AJCC-developed materials for this purpose.

6.2 CDC NPCR Reporting Requirements
Beginning with cases diagnosed 1/1/2016 and forward, CDC-NPCR will adopt the new record layout and data collection requirements as published in NAACCR Standards Volume II, Version 16. Revisions to CDC reporting requirements for 2016 are primarily due to the discontinued use of Collaborative Stage to stage cancer cases. Specific changes to the 2016 Required Status table for CDC are described below and included in Appendix E.

NPCR’s Guidance Regarding C and P Conversion

CDC’s position on how NPCR registries collect and/or consolidate directly-assigned AJCC TNM data collected for diagnosis years prior to 2016 – CDC’s NPCR is not requiring states to submit directly-assigned AJCC TNM data collected for diagnosis years prior to 2016, and thus has no requirements or preferences for how states collect and/or consolidate such data. The following provides details of CDC’s position.

Edits. NPCR required or recommended that edit sets include a minimal number of edits of pre-2016 directly-assigned AJCC TNM data.

<table>
<thead>
<tr>
<th>Primary Site, AJCC M – Ed 7, ICD3 (NPCR)</th>
<th>BLANKS ALLOWED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Site, AJCC N – Ed 7, ICD3 (NPCR)</td>
<td></td>
</tr>
<tr>
<td>Primary Site, AJCC Stage Group- Ed 7, ICDO3 (NPCR)</td>
<td></td>
</tr>
</tbody>
</table>
Primary Site, AJCC T – Ed 7, ICDO3 (NPCR)

TNM Clin Descriptor, Data of Diagnosis (NPCR)

TNM Edition Number, Date of Diagnosis (NPCR)

BLANKS SKIPPED

TNM Path Descriptor, Date of Diagnosis (NPCR)

TNM Edition Number, TNM Fields (NPCR)

If any TNM has a value, Edition cannot be blank

Calls for Data. Except for when required in special studies, CDC will not request pre-2016 directly-assigned AJCC TNM be submitted in calls for data.

Analyses. If any NPCR registries do submit such data to CDC, CDC will exclude it from all analysis files, so the presence or absence of c’s and p’s will not be an issue.

Northcon Conversion Utility. In order to assist states with implementing whatever strategy they prefer, the Northcon conversion utility is being designed to give users the option to convert or not convert pre-2016 AJCC TNM data with the c and p prefixes.

NPCR’s Guidance Regarding Software Upgrade

CDC’s position on how to handle collection of 2016 cancer cases before NAACCR Version 16-compliant software is available - For cases diagnosed in 2016 that are initially abstracted in NAACCR version 15-compliant software, the T, N, and M categories will not be converted fully (i.e., existing T, N, and M categories will be copied over but the c and p prefixes will not be added by the conversion process). When abstracting these cases registrars should be sure to clearly document the appropriate T, N, and M categories in text. For these 2016 cases, upon upgrade to NAACCR Version 16-compliant software, only the original T, N, and M categories assigned by the registrar will be retained. As a result, these cases will not pass the new v16 TNM data quality edits that require a c or p prefix for the T, N, and M data items. Therefore, the registrar will have to accurately re-assign the new T, N, and M categories (that include c and p designations) for these cases from within their NAACCR Version 16-compliant software based on review of the textual documentation.

Effective with cases diagnosed in 2016, the Collaborative Stage Data Collection System will no longer be used for deriving stage; however, the CSv2 items and algorithm will remain in place for coding historical cases diagnosed from 2004-2015. The existing CSv2 fields will also continue to be used for capturing required SSFs for 2016 diagnosis forward. Both directly-assigned SEER Summary Stage 2000 and AJCC-TNM Clinical and Pathologic Stage are now required for all cases except for those cases when stage is not applicable.

Each component of the AJCC stage is important. Even if complete AJCC TNM information is not available in the record, any piece of staging information should be collected and reported. For example, if the T and N are available but no information is available on M, the T and N should be reported.
CDC is developing an Application Program Interface (API) to assist NPCR registries with the collection of AJCC TNM Staging. The software will have two purposes:

1) Coding assistance for data entry, provided via site-specific pick lists for the clinical and pathologic T, N, and M elements and the directly-assigned stage groups based on the AJCC TNM Manual content.

2) Quality control and consolidation assistance at the central registry, provided via a derivation algorithm that will calculate clinical and pathologic stage groups based on TNM values and any related biomarkers or prognostic factors used in the AJCC staging tables. Two new calculated data items (NPCR Derived Clin Stg Grp and NPCR Derived Path Stg Grp) have been created to capture this information. These calculated values for consolidated data will be required in future data submissions to CDC.

With permission from AJCC, the full CDC API will be incorporated into the CDC Registry Plus software and also made available to NPCR grantees with their own home-grown software systems. For NPCR grantees that use vendor-based systems for their central registry, the API will be made available with the derivation functionality operational, but access to the copyright-protected AJCC content will be disabled. Commercial software vendors for central registries and hospitals should contact AJCC (Martin Madera, mmadera@facs.org) to discuss using copyright-protected AJCC content in their application. All NPCR grantees will be required to use the API to derive and submit the new NPCR calculated clinical and pathologic stage group data items.

NPCR will include edits in the NAACCR 2016 metafile to help ensure standardized data collection of all directly coded TNM items throughout the NPCR program. There will be edits that validate codes for each item and also edits that enforce relationships among data items. Where NPCR edits differ from those of other standard setters, data from NPCR registries will be expected to pass NPCR’s edits.

For the implementation of clinical and pathologic indicators for the AJCC T, N, and M data items (see section 4.2) CDC will not require conversion of existing TNM data to 2016 data standards. CDC will work with the NPCR registries on managing TNM data from 2015 diagnoses and earlier submitted by CoC hospitals that may have c and p prefixes added retroactively.

**Required Site-Specific Factors:** SSFs necessary to calculate Derived Summary Stage 2000 or Derived AJCC 7 Stage Group (for Collaborative Stage) are no longer required for cases diagnosed in 2016; however, site-specific factors that impact directly-assigned AJCC-TNM 7th Edition Stage Group (e.g. PSA for prostate) or that are prognostic factors of interest, remain important to collect for cancer surveillance. The Collaborative Stage SSF data items will continue to be used for this purpose. SSFs that will be required by CDC-NPCR are listed in Tables 1 and 2 below. **CS Version Input Original and CS Version Input Current must continue to be populated for as long as the SSFs are being collected using the CS DLL.**

<table>
<thead>
<tr>
<th>Site (CS Schema)</th>
<th>SSF</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix</td>
<td>SSF11</td>
<td>Histopathologic Grading</td>
</tr>
<tr>
<td>GIST Peritoneum</td>
<td>SSF 5 and 10</td>
<td>Mitotic Count; Location of Primary Tumor</td>
</tr>
<tr>
<td>GIST Esophagus, GIST Small Intestine, GIST Stomach</td>
<td>SSF 6</td>
<td>Mitotic Count</td>
</tr>
<tr>
<td>GIST Appendix, GIST Colon, GIST Rectum</td>
<td>SSF 11</td>
<td>Mitotic Count</td>
</tr>
<tr>
<td>Mycosis Fungoides</td>
<td>SSF 1</td>
<td>Peripheral Blood Involvement</td>
</tr>
<tr>
<td>Placenta</td>
<td>SSF 1</td>
<td>Prognostic Scoring Index</td>
</tr>
</tbody>
</table>
Table 1. CDC NPCR SSFs Required for Directly-Assigned AJCC TNM Stage

<table>
<thead>
<tr>
<th>Site (CS Schema)</th>
<th>SSF</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>SSF 1, 8 and 10</td>
<td>PSA Lab Value, Gleason Score</td>
</tr>
<tr>
<td>Testis</td>
<td>SSF 13, 15, 16</td>
<td>Post Orchiectomy AFP, hCG, and LDH Range</td>
</tr>
</tbody>
</table>

Table 2. CDC NPCR SSFs required by NPCR (but not for AJCC Staging)

<table>
<thead>
<tr>
<th>Site (CS Schema)</th>
<th>SSF</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain, CNS Other, Intracranial Gland</td>
<td>1</td>
<td>WHO Grade</td>
</tr>
<tr>
<td>Breast</td>
<td>1</td>
<td>ERA</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>PRA</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>HER2: IHC Value</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>HER2: IHC Interpretation</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>HER2: FISH Interpretation</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>HER2: CISH Interpretation</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>HER2: Result of other test</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>HER2: Summary Result testing</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>Combination of ERA, PRA and HER2 Testing</td>
</tr>
</tbody>
</table>

Newly Required Data Items (See also Appendix E):
Census County 1990 [94] – Central Registry Only
Census County 2000 [95] – Central Registry Only
Census County 2010 [96] – Central Registry Only
Tumor Size Summary [756]
TNM Path T [880]
TNM Path N [890]
TNM Path M [900]
TNM Path Stage Grp [910]
TNM Path Descriptor [920]
TNM Clin T [940]
TNM Clin N [950]
TNM Clin M [960]
TNM Clin Stage Grp [970]
TNM Clin Descriptor [980]
TNM Edition Number [1060]
RX Summ-Surg/Rad Seq [1380]
RX Summ Systemic/Sur Seq [1639]
Rural Urban Continuum 2013 [3312] – Central Registry Only
NPCR Derived Clin Stg Grp [3650] – Central Registry Only
NPCR Derived Path Stg Grp [3655] – Central Registry Only
**CSv2 Data Items that Continue to be Required:**
Regional Nodes Positive [820]
Regional Nodes Examined [830]
Lymph-Vascular Invasion [1182]
CS Version Input Original [2935]
CS Version Input Current [2937]
CS Site-Specific Factors 1, 2, 5, 6, 8, 9, 10, 11, 13, 14, 15, 16, 25 [2880, 2890, 2920, 2930, 2862-2865, 2867-2870, 2879] (See Tables 1 and 2)

**Data Items No Longer Required/Required Historically (See Appendix E):**
CS Site-Specific Factors 3, 4, 7, 12, 17-24 [2900, 2910, 2861, 2866, 2871-2878]
CS Tumor Size [2800]
CS Extension [2810]
CS Tumor Size/Ext Eval [2820]
CS Lymph Nodes [2830]
CS Mets at DX [2850]
CS Version Derived [2936]
Derived SS2000 [3020]
Derived SS2000-Flag [3050]
CS Lymph Nodes Eval [2840]
CS Mets Eval [2860]
Derived AJCC-7 T [3400]
Derived AJCC-7 T Descript [3402]
Derived AJCC-7 N [3410]
Derived AJCC-7 N Descript [3412]
Derived AJCC-7 M [3420]
Derived AJCC-7 M Descript [3422]
Derived AJCC-7 Stage Grp [3430]
Over-ride CS 1-20 [3750-3769]

**Newly Reportable Conditions/Tumors:**
In 2014 and 2015 SEER added new reportable histology terms to their Program and Coding Manual. These terms had not been included in any ICD-O-3 errata and therefore were not addressed throughout the cancer surveillance community. CDC has reviewed the terms and determined that the following are reportable. While there has not been an official errata to address these histology terms, CDC recommends adding them to ICD-O-3 Manuals and educating reporting sources about these new updates.

1. Non-invasive mucinous cystic neoplasm of the pancreas with high-grade dysplasia replaces mucinous cystadenocarcinoma, non-invasive (8470/2).
2. Solid pseudopapillary neoplasm of pancreas (8452/3) is synonymous with solid pseudopapillary carcinoma (C25._)
3. Based on pathologist consultation, metastases have been reported in some cystic pancreatic endocrine neoplasm (CPEN) cases. With all other pancreatic endocrine tumors now considered malignant, CPEN will also be considered malignant, until proven otherwise. Most CPEN cases are non-functioning and are REPORTABLE using histology code 8150/3, unless the tumor is specified as a neuroendocrine tumor, grade 1 (assign code 8240/3) or neuroendocrine tumor, grade 2 (assign code 8249/3)
4. Laryngeal intraepithelial neoplasia, grade III (LINIII) (8077/2), C320-C329
5. Squamous intraepithelial neoplasia, grade III (SINIII) (8077/2), except Cervix and Skin

6. Mature teratoma of the testes in adults is malignant and REPORTABLE as 9080/3, but continues to be non-reportable in prepubescent children (9080/0). The following provides additional guidance:
   - Adult is defined as post puberty
   - Pubescence can take place over a number of years
   - Do not rely solely on age to indicate pre or post puberty status. Review all information (physical history, etc.) for documentation of pubertal status. When testicular teratomas occur in adult males, pubescent status is likely to be stated in the medical record because it is an important factor of the diagnosis.
   - Do not report if unknown whether patient is pre or post pubescence. When testicular teratoma occurs in a male and there is no mention of pubescence, it is likely that the patient is a child, or pre-pubescent, and the tumor is benign.

6.3 NCI SEER Reporting Requirements

All SEER registries will submit directly-assigned clinical and pathologic TNM 7th Edition T, N, M and either directly-assigned stage group values or stage group values assigned by the SEER software. Approximately one half of SEER registries will continue the collection of CS v.02.05 for cases diagnosed 1/1/2016 and forward. Those registries will use the CS algorithm to calculate the SEER Summary Stage 2000 and the Derived AJCC TNM 7th Edition values (in addition to coding the directly-assigned fields). SEER registries not collecting CS will submit the directly-assigned SEER Summary Stage 2000. All SEER registries will continue to collect the required CSv2 SSFs. In addition to the SSFs, Regional Nodes Positive and Examined and Lymph-vascular Invasion will continue to be required. Changes in NCI SEER requirements for 2016 are listed in Appendix F.

<table>
<thead>
<tr>
<th>Schema/Chapter</th>
<th>SSF</th>
<th>Rationale for no longer needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>#3</td>
<td>Becomes pathologic T</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>#1</td>
<td>Becomes pathologic T</td>
</tr>
<tr>
<td>Appendix</td>
<td>#2</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Carcinoid</td>
<td>#2</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Colon/Rectum</td>
<td>#2</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Esophagus/GE</td>
<td>#1</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Junction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lacrimal Gland</td>
<td>#3</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Melanoma Skin</td>
<td>#3</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Merkel Cell</td>
<td>#3</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>NET Colon</td>
<td>#2</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>NET Rectum</td>
<td>#2</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>NET Stomach</td>
<td>#1</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Skin Eyelid</td>
<td>#3</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Small Intestine</td>
<td>#2</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>Stomach</td>
<td>#1</td>
<td>Becomes clinical N</td>
</tr>
<tr>
<td>BileDucts</td>
<td>#10</td>
<td>T4 definition</td>
</tr>
<tr>
<td>Intrahepatic</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
For the implementation of clinical and pathologic indicators for the AJCC T, N, and M data items (see section 4.2) NCI SEER will not require conversion of existing TNM data to 2016 data standards. NCI SEER will work with our registries on managing TNM data from 2015 diagnoses and earlier submitted by CoC hospitals that may have c and p prefixes added retroactively.

SEER registries will make use of the SEER Registrar Staging Assistant (SEER*RSA) to help them assign stage and code predictive and prognostic factors. Data from the SEER*RSA will be made available in SEER*DMS and on the SEER website. SEER*RSA data are provided via both an API and software libraries. The centerpiece of the new setup is the SEER*API, which is a mechanism used to “get” data. The staging section of the SEER*API knows how to get both UICC TNM and CSv02.05.50 data and how to calculate CS stage, TNM stage, and Combined Stage. The API has the capability to return the same information that is currently returned by the CS DLL for CSv02.05.50. The API also has the capability to return UICC TNM data, such as the list of schemas to be collected for cases diagnosed January 1, 2016 and forward, which data items are required for staging for each schema, which SSFs are required to be collected by the various standard setters for TNM, what the permissible values are for each data item, as well as being able to stage cases using UICC TNM staging rules. The SEER*API can be used directly free of charge. Visit http://api.seer.cancer.gov for more information. Alternatively, a Java library can be used in an offline capacity. This library is open source and can be accessed at https://github.com/imsweb/staging-client-java. A C++ library is coming soon.

6.4  CCCR Reporting Requirements

Beginning with cases diagnosed on or after January 1, 2016, the Canadian Council of Cancer Registries (CCCR) will implement the data collection, and submission requirements as published in the Standards Volume II, Version 16, Chapter VIII, Required Status Table CCCR column.

The Canadian registries will not be implementing any of the new data items in section 2 for 2016 diagnoses. None of the changed data items in section 3 are applicable to Canada for 2016 diagnosis.

Canada will continue to use the Collaborative Stage Data Collection System Version 02.05 to stage their new cases until the end of the 2016 diagnosis year. Beginning with cases diagnosed January 1, 2017, Canada plans to implement TNM stage data collection to coincide with the expected release of the AJCC Cancer Staging Manual 8th Edition. Specific stage variables that will be required for collection are not yet defined.

Cases will be submitted to the Canadian Cancer Registry during Statistic Canada’s Canadian Cancer Registry Call for Data. Provincial/Territorial registries can reference the Canadian Cancer Registry Input Record layout of the Canadian Cancer Registry System Guide for a more comprehensive listing.

Newly Reportable Conditions/Tumors:

In 2012, the CCCR added the following newly reportable condition/term: non-invasive mucinous cystic neoplasm of the pancreas with high-grade dysplasia replaces mucinous cystadenocarcinoma, non-invasive (8470/2).
Effective in 2015, the following conditions/tumors became reportable:

1) Solid pseudopapillary neoplasm of pancreas (8452/3) is synonymous with solid pseudopapillary carcinoma (C25._)
2) Cystic pancreatic endocrine neoplasm (CPEN) (8150/3), unless the tumor is specified as a neuroendocrine tumor, grade 1 (assign code 8240/3) or neuroendocrine tumor, grade 2 (assign code 8249/3)
3) Laryngeal intraepithelial neoplasia, grade III (LINIII) (8077/2), C320-C329
4) Squamous intraepithelial neoplasia, grade III (SINIII) (8077/2), except Cervix and Skin
5) Mature teratoma of the testes in adults (9080/3), but non-reportable in prepubescent children (9080/0).

7  Summary for Central Cancer Registries

7.1  Record Length, New Data Items, and Changed Data Items

7.1.1  Record Length
Significant changes have been made to the Record Layout; see section 3.1 for details.

7.1.2  New Data Items
A total of thirty new data items have been implemented. Central cancer registries should review each new data item to determine which are required to be reported to meet individual requirements to national standard setters (see section 6). See section 2 and Standards Volume II, Version 16 for detailed description of the new fields.

7.1.3  Changed Data Items
Significant changes have been made to existing data items. See section 3 and Standards Volume II, Version 16 for details.

7.2  Staging Transition
See section 6 and the Standards Volume II, Version 16 Required Status Table (chapter VIII) to determine which staging data items are required to be collected by the various standards setters. Communicating these changes to the reporting facilities and to software vendors should be undertaken as soon as possible.

7.3  ICD-O-3 Histologies
Consistent with decisions of the standard setters, there will not be any changes to reportable histology codes for 2016 diagnoses. Since new terms and codes were previously approved for use by the College of American Pathologists, hospital registrars should find out if their pathologists are using new terms that have not been officially adopted for cancer surveillance in North America. If so, they should report those conditions to central registries using the currently acceptable codes, as enumerated in Appendix D. The contents of the table have not been changed since the ICD-O-3 Implementation Update document was released.

Central Registries need to review reportability changes specific to their respective standards setters (see section 6).
7.4 Central Registry Edits
The central cancer registry should review the EDITS metafile for Standards Volume II, Version 16 (see section 5), to determine the edits that it will implement for incoming records and for consolidated items in the central registry’s database. Central cancer registries should review the NAACCR v16 metafile documentation in parallel with the newly required data items and include every applicable edit in their state-specific EDITS metafile. Of particular note are the new TNM edits that have been written and tested during the past year.

Central cancer registries should note that edits in the metafile may need to be revised to accommodate central registry-specific or state-specific reporting requirements, and that special edits may need to be developed for central registry-specific data items. Implementation, testing, and distribution of central registry-specific EDITS metafiles to reporting facilities and vendors should be considered as central cancer registries develop their requirements for 2016 reporting. Central cancer registries that generate and distribute their own metafiles should have a plan to keep them updated.

The central cancer registry should evaluate the time required to correct errors in previous years’ data that appear after retrospectively applying new edits, particularly when there are no guidelines that limit diagnosis years to which the new edit(s) should be applied. Taking into account the relative importance of the affected data items and the amount of time required to edit the records, central registries should prioritize and fix these retrospectively-identified errors.

7.5 Software Implementation Plan
Central cancer registries that receive submissions from facilities using commercial software to generate their files should pay close attention to the new releases of these products and coordinate their own Standards Volume II, Version 16 implementation plan accordingly. Every new vendor version should be reviewed to ensure compliance with the new record layout version and with registry requirements, before files are merged into the central cancer registry’s database. Various methods can be used to test a data submission for compliance with standards, including visual review and the application of an EDITS metafile. The use of a test environment into which submissions can be loaded and viewed as they would appear in the active database is recommended.

A reporting facility’s first transmission in Standards Volume II, Version 16 should be tested as thoroughly as possible to identify layout and/or code problems before v16 records are accepted from that facility. Some central registries require a “test file” from each software vendor or reporting facility.

7.6 Communication with Reporting Facilities and Software Vendors
Central cancer registries will need to distribute their implementation plan and timeline to reporting facilities and software vendors as early as possible. The communication should include a new reportability list and an updated list of required data items, including explicit instructions for state/province/territory-specific items. Changes to the implementation plan or the timeline should be forwarded immediately to all affected parties. Reporting facilities that are not CoC-accredited cancer programs may be less aware of upcoming changes and may need more transition time. Facilities that do not use a vendor for their reporting software will need extra attention.

Central registries relying on vendor software for their own systems and/or their reporting facilities should be aware that delays in the communication of this information to software vendors may result in a delay in receiving and/or incorporating 2016 cases.
Until each reporting facility is fully converted to Standards Volume II, Version 16, vendors and central registries will need to provide continued support for reporting and processing of records diagnosed 2015 and earlier in Standards Volume II, Version 15 record format.

7.7 Education and Training
Central cancer registries will have to provide training to their reporting facilities on changes identified in this document. The most significant changes are related to the direct coding of AJCC TNM values and SEER Summary Stage. Trainings should focus on continued education of coding these fields. Central registry staff will also have to be trained on newly-required data items, and on rules for consolidation of newly required information coming from multiple sources for the same tumors. The NAACCR Data Item Consolidation Manual prescribing best practices for many standard data items should be distributed to central registry staff, with the rules followed manually until they can be implemented automatically in the central registry software.

8 Summary for Software Developers and Vendors
All software vendors will be responsible for identifying required software changes, accommodating new and changed data items; providing support for the transition away from CS to TNM and directly coded SEER Summary Stage; performing data conversion where necessary, and providing continued access to updated supplementary coding resources. Vendors will also need to address testing and implementation issues, as well as technical support and training. Instruction to development staff should address the following:

8.1 Identify Software Changes
Software specifications generated to adapt programs will be vendor-specific and will vary for reporting facility applications and central registry applications. Specifically, vendors will need to accommodate the following changes and additions documented in this guide:

<table>
<thead>
<tr>
<th>Section Number</th>
<th>Section Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>New data items (some items may require additional codes and labels for pick lists)</td>
</tr>
<tr>
<td>3.1</td>
<td>Record layout changes</td>
</tr>
<tr>
<td>3.2</td>
<td>Addition of Clinical and Pathologic Indicators to AJCC T, N, and M</td>
</tr>
<tr>
<td>3.3</td>
<td>Sex – code 3 definition change</td>
</tr>
<tr>
<td>3.4</td>
<td>Census codes name change – ( for central registry software)</td>
</tr>
<tr>
<td>3.5</td>
<td>TNM Staged By data items length increase and code conversion</td>
</tr>
<tr>
<td>3.6</td>
<td>Wording changes in description or rationale - only a consideration for help systems</td>
</tr>
<tr>
<td>3.7</td>
<td>SEER Coding Sys-Current and Original [2120 and 2130]</td>
</tr>
<tr>
<td>4.2</td>
<td>Addition of Clinical and Pathologic indicators to AJCC T, N, and M values</td>
</tr>
<tr>
<td>5</td>
<td>EDITS</td>
</tr>
<tr>
<td>6.1</td>
<td>CoC Reporting Requirements. New c and p TNM prefix indicators require additional codes and labels for pick lists.</td>
</tr>
<tr>
<td>6.2</td>
<td>CDC NPCR Reporting Requirements</td>
</tr>
<tr>
<td>6.3</td>
<td>NCI SEER Reporting Requirements</td>
</tr>
<tr>
<td>6.4</td>
<td>CCCR Reporting Requirements</td>
</tr>
</tbody>
</table>
8.2 Data Conversion
The length of TNM Clin Staged By and TNM Path Staged By data items were expanded to 2 digits to accommodate new codes, see section 3.5. The NAACCR Record Version will be converted from 150 to 160. Any conversion crosswalks will be made available on the NAACCR Web site, as well as incorporated into Northcon 16, the CDC conversion program. Northcon 16 will be available six weeks from the receipt of the final detailed specifications. Modification to the specifications may cause delay in releasing the program.

8.3 Staging Transition Support
The current version of CS, CSv02.05, will not change in 2016. The CSv2 items and algorithm will remain for cases diagnosed from 2004 to 2015 for some registries.

Consider displaying the Site Specific Factor data items for viewing and/or editing on the screen where the directly-assigned T, N, and M are coded (see section 6 for standard setter requirements). See section 6.2 for a discussion of the API to assist NPCR registries with the collection of AJCC TNM staging and section 6.3 for information about the SEER API for TNM stage assignment.

Commercial software vendors for central registries and reporting facilities should contact AJCC (Martin Madera, mmadera@facs.org) to discuss using copyright-protected AJCC content in their application.

8.4 SEER Hematopoietic & Lymphoid Database
The latest version of the Hematopoietic & Lymphoid Database by NCI SEER was published in January 2015. The Hematopoietic & Lymphoid Database is available in two formats: a web-based tool and as stand-alone software. Vendors may want to consider inclusion of a link to the web-based format from within their software as updates are automatic: users do not have to install anything to access the latest revisions, and this option eliminates problems for users who do not have permission to install software on their work computers. However, vendors should give consideration to the fact that users may need the stand-alone software because they may not have access to the Internet. NCI SEER has announced that they will be implementing a new feature that will automatically update the standalone version whenever the user accesses the Internet.

8.5 SEER*Rx Drug Database
The latest version of the SEER*Rx drug database was released in September 2014 (web version) and June 2015 (software update). If you have not already done so, vendors may want to consider inclusion of a link to the web-based format from within their software as updates are automatic: users do not have to install anything to access the latest revisions, and this option eliminates problems for users who do not have permission to install software on their work computers. However, vendors should give consideration to the fact that users may need the standalone software because they may not have access to the Internet.

8.6 Programming, Testing, and Implementation
Clear communication with central cancer registries and reporting facility customers is critical to avoid delays in delivering software that can deliver and process 2016 cases. Software vendors should provide programming instructions to support the necessary changes for Standards Volume II, Version 16, as well as testing (if time allows, beta site testing) and implementing the items listed elsewhere in this document. Software vendors need to revise/develop, test, distribute, and install software prior to implementation dates set by standard setting organizations and central cancer registries.
Central cancer registries may require software vendors to submit test files prior to approval in reporting in the Standards Volume II, Version 16 format. Testing should determine that appropriate values are validated within the software. Testing should also accommodate verification of revisions for data import and export, revisions to the software interface, addition of look-ups for new and changed data items where applicable, data entry verifications internal to the software (if available within the software), data item consolidation where applicable, and standard as well as ad hoc report writing. Any changes to the implementation timeline should be immediately reported to all involved parties. If there are delays to the standards or errata that have not yet been identified, the software vendor programs will be at risk of delay. Individual changes to the state-specific state requestor section must also be communicated early in the coding and implementation period in order to be accommodated for software release.

8.7 New Online Help Files
Changes to any software’s online help system (if available) will need to be made in conjunction with Standards Volume II, Version 16-related changes made to the software. New Registry Plus Online Help for Standards Volume II, Version 16 will be made available from CDC. For vendors that do not use CDC’s Registry Plus Online Help within their software, or those that supplement it with extra information, updates will need to be made to online help.

8.8 Technical Support and Training
Software vendors are expected to support the data changes in Standards Volume II, Version 16 in the software and provide their clients with training and documentation appropriate to use the updated software. For reporting facility level applications, this will include instruction regarding export of records for transmission to their respective central registries in the correct format with correctly coded and error free data, as well as import from their previously supported casefinding interface. Documentation to support the updated software may include information presented via the software’s online help system and/or training or tutorial guides. Training and support on new coding rules should be referred to the appropriate standard setting organization.

8.9 Communication with Central Cancer Registries and Hospital Registries
Software vendors should provide a timeline to the central registries indicating when they will be able to produce software that is able to process and produce Standards Volume II, Version 16 case records. Vendors should have an avenue for timely communication from all central registry clients so that proper support of state-specific changes in required data reporting are made, including mapping of state-specific data items in the state/requestor section of the record. In addition, vendors should implement state edit sets as provided by the registries. Central registry clients should be aware that delays in communication of this information from state registry clients to the software vendor may result in a delay in reporting 2016 cases. Until each state registry client is fully converted to Standards Volume II, Version 16, vendors will need to provide continued support for reporting and processing of records diagnosed 2015 and earlier in NAACCR Version 15.0 record format.

9 Summary for Hospital Cancer Registrars and Reporting Facilities
The CoC, NPCR, SEER, and CCCR would like to collectively thank hospital registrars for their perseverance in excellence during this time of annual change. Cancer registration is an ever-evolving field, and without the
continued level of dedication demonstrated by hospital registrars across North America, these organizations would not be able to adapt to change and meet their goals.

Although there are numerous new and revised data items for 2016, many of the changes are intended for implementation at the central registry level (e.g., derivation of new derived staging data items, geocoded data items), or are informational in nature (e.g., wording changes to accommodate EHR reporting). The scope of changes being implemented at the level of the hospital registry is minimal. There are a few changes that registrars need to be aware of in order to smoothly transition to using new and changed data items and updated software. In particular, there are new data items being implemented to accommodate the transition away from Collaborative Stage. It is imperative that hospital registrars be familiar with the specific reporting requirements of the standard setter(s) (see section 6) to which their data are ultimately reported, as there are differences in requirements, specifically for staging information.

Cases diagnosed on or after January 1, 2016, must be collected and reported in accordance with the standards and definitions of the Standards Volume II, Version 16.

9.1 Prioritize Case Abstracting
Registrars should prioritize their abstracting. Ideally, abstracting of cases diagnosed prior to January 1, 2016, should be completed before converting registry data or beginning to use Standards Volume II-based, Version 16 software upgrades.

9.2 New Data Items
The following new data items all are being implemented to accommodate transition away from Collaborative Stage:

- Mets at DX-Bone [1112]
- Mets at DX-Brain [1113]
- Mets at DX-Distant LN [1114]
- Mets at DX-Liver [1115]
- Mets at DX-Lung [1116]
- Mets at DX-Other [1117]
- Tumor Size Clinical [752]
- Tumor Size Pathologic [754]
- Tumor Size Summary [756]

**NOTE:** Reporting requirements of the standard setter(s) for these new data items vary (see section 6).

9.3 Changed Data Items
The majority of changes to existing data items were made for the purpose of implementing updated terminology (Sex code 3, replacement of the label hermaphrodite), interoperability (wording changes to accommodate EHRs) or are not applicable at the level of the reporting facility (changes to Census industry and occupation data items) (see section 3). Registrars need to be aware of the following changes:

9.3.1 Addition of Clinical and Pathologic Indicators to AJCC T, N, and M
Clinical and pathologic indicators are being added to the AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900]. The indicators are to be added by modifying the existing values for the individual T, N, and M data items and adding a minimal number of new codes, while deleting some existing codes. The revisions will be incorporated into software look ups to allow for selection of necessary ‘p’ values within the clinical
codes and selection of necessary ‘c’ values within the pathologic codes when abstracting. See section 4.2 for complete details.

9.3.2 TNM Path Staged By [930] and TNM Clin Staged By [990]
The length of both data items has been expanded to 2 digits to accommodate new codes. Refer to the most recent version of FORDS for revised coding instructions.

9.3.3 SEER Coding Sys-Current and Original [2120 and 2130]
Code G was added to accommodate the 2016 SEER Coding Manual. If your registry reports to a SEER central registry you will need to ensure that your software vendor has this new value appropriately defaulted.

9.4 Staging Transition Issues
Although the field of cancer registration is transitioning away from the Collaborative Stage system for staging cancer cases, use of CsV2 version 02.05.50 data items and derivations will continue for the abstraction of cases diagnosed from 2004-2015, as well as for continued collection of Site-specific Factors for cases diagnosed in 2016. Canadian facilities will continue to use CsV2 for all staging items. As mentioned earlier, hospital registrars need to familiarize themselves with the differing stage data item requirements by standard setter (see section 6). Some important highlights follow:

- As always, central registries will be providing support to their reporting facilities in the form of clear documentation of reporting requirements.
- Directly-assigned SEER Summary Stage 2000 [759] is required for facilities reporting to CDC NPCR state central cancer registries and the CoC NCDB, however, some facilities reporting to NCI SEER state central cancer registries will be required to abstract either SEER Summary Stage 2000 or Collaborative Stage.
- The new Tumor Size Summary [756] data item is required for facilities reporting to CDC NPCR state central cancer registries and the CoC NCDB, while the new Tumor Size Clinical [752] and Tumor Size Pathologic [754] data items are required for facilities reporting to NCI SEER state central cancer registries.
- Some facilities reporting to NCI SEER state central cancer registries and all Canadian registries will continue to use CsV2 version 02.05.50 data items and derivations for the abstraction of cases diagnosed in 2016.
- In 2016, use of CsV2 version 02.05.50 will continue to collect CS Site-Specific factors using the same NAACCR data layout and definitions. For CoC approved reporting hospitals reporting to CoC NCDB, and reporting facilities that report to NCI SEER central registries, there are no changes in CS SSF reporting requirements for 2016. However, facilities that report only to CDC NPCR central registries will need to be aware of changes in CS SSF reporting requirements (see section 6).

9.4.1 New AJCC TNM Stage Data Item Edits
A new sub-workgroup of the NAACCR EDITS Workgroup was formed to specifically generate new, more robust data quality edits for the AJCC T, N, M and stage data items. The work product of this workgroup to-date will be incorporated into the NAACCR Version 16 edits metafile. As a result, registrars should be aware that they may need to address new edit errors upon the implementation of the v16 edits within their abstraction software.
9.5 Conversion Consideration
Conversion from NAACCR version 15- to NAACCR version 16-based software affects very few data items (primarily AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900], TNM Path Staged By [930], TNM Clin Staged By [990], and NAACCR Record Version [50]). However, it is always good practice for registrars to review and apply data quality edits to their data and resolve any coding discrepancies or edit errors prior to conversion.

**Northcon Conversion Utility.** In order to assist states with implementing whatever strategy they prefer, the Northcon conversion utility is being designed to give users the option to convert or not convert pre-2016 AJCC TNM data with the c and p prefixes.

9.6 Communicate with Software Vendors and Central Cancer Registries
Hospital registries should contact their software vendors to ascertain when the Version 16 software upgrade will be available, and then make arrangements with their facility IT staff to have someone available to oversee the upgrade process. Schedule firm implementation dates as early as possible to avoid delays.

Registries that are prepared for and have an interest in being involved in early implementation of software upgrades should consider offering to be a beta test site for their software provider. This will allow the registry to obtain the software upgrades at the earliest opportunity and contribute valuable feedback regarding the upgrade process to their software provider (thus facilitating upgrades for other registries using the software).

When planning for the software upgrade, registries should contact their central registries to find out when they may begin transmitting in the upgraded version as this will impact the implementation date scheduled with their software vendor and facility IT staff.

9.7 Education and Training
Registrars and abstractors should attend education and training provided by regional, state, or national programs. These may include any combination of webinars, face-to-face training sessions at meetings, self-instructional material, and making time to work slowly through coding while becoming familiar with the changes. In particular, registrars should plan on attending or reviewing the AJCC Curriculum for Registrars found at: [https://cancerstaging.org/CSE/Registrar/Pages/AJCC-Curriculum.aspx](https://cancerstaging.org/CSE/Registrar/Pages/AJCC-Curriculum.aspx)

In addition, registrars may find the following resources helpful:

- [https://www.facs.org/quality-programs/cancer](https://www.facs.org/quality-programs/cancer)
- [http://www.cdc.gov/cancernpcr/index.htm](http://www.cdc.gov/cancernpcr/index.htm)
- [http://www.ncra-usa.org/i4a/pages/index.cfm?pageid=1](http://www.ncra-usa.org/i4a/pages/index.cfm?pageid=1)
10 Appendix A Conversion of TNM Path Staged By [930] and TNM Clin Staged By [990]

The following conversion tables are designed to expand the 1-character codes formerly assigned to the TNM Path Staged By and TNM Clin Staged By data items to 2-character codes. Refer to the most recent version of FORDS for code definitions. The conversion below will be performed across all diagnosis years (cases diagnosed in 2016 for which abstraction is started in NAACCR Version 15-compliant software will be converted). These conversions are mutually exclusive. Blank fields are not included in the below tables and should remain blank.

Part 1: TNM Clin Staged By and TNM Path Staged By codes 0-8 Conversion

The first step of the conversion is a direct conversion of the 1-character TNM Clin Staged By and TNM Path Staged By codes to the corresponding 2-character codes.

<table>
<thead>
<tr>
<th>TNM Clin Staged By and TNM Path Staged By (Version 15)</th>
<th>Convert TNM Clin Staged By and TNM Path Staged By (Version 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>00</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>2</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>6</td>
<td>30</td>
</tr>
<tr>
<td>7</td>
<td>50</td>
</tr>
<tr>
<td>8</td>
<td>88</td>
</tr>
</tbody>
</table>

Part 2: TNM Clin Staged By and TNM Path Staged By code 9 Conversion

The second step of the conversion determines how to convert TNM Clin Staged By (see A below) and TNM Path Staged By (see B below) code 9 using the related TNM T, N, M, and Stage Group values.

A.

<table>
<thead>
<tr>
<th>If TNM Clin Staged By (version 15) = 9 and</th>
<th>Then convert TNM Clin Staged By (version 16) to</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNM Clin T (version 15) =</td>
<td>TNM Clin N (version 15) =</td>
</tr>
<tr>
<td>Blank</td>
<td>Blank</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>88</td>
<td>88</td>
</tr>
</tbody>
</table>

B.

<table>
<thead>
<tr>
<th>If TNM Path Staged By (version 15) = 9 and</th>
<th>Then convert TNM Path Staged By (version 16) to</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNM Path T (version 15) =</td>
<td>TNM Path N (version 15) =</td>
</tr>
<tr>
<td>Blank</td>
<td>Blank</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>88</td>
<td>88</td>
</tr>
</tbody>
</table>

C. Remaining cases with TNM Clin Staged By and TNM Path Staged By = 9 are to be converted to 99
11 Appendix B Data Items with Wording Changes to Accommodate EHR Reporting

<table>
<thead>
<tr>
<th>Data Item Name</th>
<th>Item #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accession Number--Hosp</td>
<td>550</td>
</tr>
<tr>
<td>Primary Payer at DX</td>
<td>630</td>
</tr>
<tr>
<td>RX Hosp--Surg Prim Site</td>
<td>670</td>
</tr>
<tr>
<td>RX Hosp--Scope Reg LN Sur</td>
<td>672</td>
</tr>
<tr>
<td>RX Hosp--Surg Oth Reg/Dis</td>
<td>674</td>
</tr>
<tr>
<td>RX Hosp--Reg LN Removed</td>
<td>676</td>
</tr>
<tr>
<td>RX Hosp--Hormone</td>
<td>710</td>
</tr>
<tr>
<td>RX Hosp--Other</td>
<td>730</td>
</tr>
<tr>
<td>RX Hosp--Surg Site 98-02</td>
<td>746</td>
</tr>
<tr>
<td>RX Hosp--Scope Reg 98-02</td>
<td>747</td>
</tr>
<tr>
<td>RX Hosp--Surg Oth 98-02</td>
<td>748</td>
</tr>
<tr>
<td>Place of Death--State</td>
<td>1942</td>
</tr>
<tr>
<td>Place of Death--Country</td>
<td>1944</td>
</tr>
<tr>
<td>NPI--Inst Referred To</td>
<td>2425</td>
</tr>
<tr>
<td>Institution Referred To</td>
<td>2420</td>
</tr>
<tr>
<td>Text--DX Proc--PE</td>
<td>2520</td>
</tr>
<tr>
<td>Text--DX Proc--X-ray/Scan</td>
<td>2530</td>
</tr>
<tr>
<td>Text--DX Proc--Scopes</td>
<td>2540</td>
</tr>
<tr>
<td>Text--DX Proc--Lab Tests</td>
<td>2550</td>
</tr>
<tr>
<td>Text--DX Proc--Op</td>
<td>2560</td>
</tr>
<tr>
<td>Text--DX Proc--Path</td>
<td>2570</td>
</tr>
<tr>
<td>Text--Primary Site Title</td>
<td>2580</td>
</tr>
<tr>
<td>Text--Histology Title</td>
<td>2590</td>
</tr>
<tr>
<td>Text--Staging</td>
<td>2600</td>
</tr>
<tr>
<td>RX Text--Surgery</td>
<td>2610</td>
</tr>
<tr>
<td>RX Text--Radiation (Beam)</td>
<td>2620</td>
</tr>
<tr>
<td>RX Text--Radiation Other</td>
<td>2630</td>
</tr>
<tr>
<td>RX Text--Chemo</td>
<td>2640</td>
</tr>
<tr>
<td>RX Text--Hormone</td>
<td>2650</td>
</tr>
<tr>
<td>RX Text--BRM</td>
<td>2660</td>
</tr>
<tr>
<td>RX Text--Other</td>
<td>2670</td>
</tr>
<tr>
<td>Text--Remarks</td>
<td>2680</td>
</tr>
<tr>
<td>Text--Place of Diagnosis</td>
<td>2690</td>
</tr>
<tr>
<td>Comorbid/Complication 1</td>
<td>3110</td>
</tr>
<tr>
<td>Comorbid/Complication 2</td>
<td>3120</td>
</tr>
<tr>
<td>Comorbid/Complication 3</td>
<td>3130</td>
</tr>
<tr>
<td>Comorbid/Complication 4</td>
<td>3140</td>
</tr>
<tr>
<td>Comorbid/Complication 5</td>
<td>3150</td>
</tr>
<tr>
<td>Comorbid/Complication 6</td>
<td>3160</td>
</tr>
<tr>
<td>Comorbid/Complication 7</td>
<td>3161</td>
</tr>
<tr>
<td>Data Item Name</td>
<td>Item #</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Comorbid/Complication 8</td>
<td>3162</td>
</tr>
<tr>
<td>Comorbid/Complication 9</td>
<td>3163</td>
</tr>
<tr>
<td>Comorbid/Complication 10</td>
<td>3164</td>
</tr>
<tr>
<td>Secondary Diagnosis 1</td>
<td>3780</td>
</tr>
<tr>
<td>Secondary Diagnosis 2</td>
<td>3782</td>
</tr>
<tr>
<td>Secondary Diagnosis 3</td>
<td>3784</td>
</tr>
<tr>
<td>Secondary Diagnosis 4</td>
<td>3786</td>
</tr>
<tr>
<td>Secondary Diagnosis 5</td>
<td>3788</td>
</tr>
<tr>
<td>Secondary Diagnosis 6</td>
<td>3790</td>
</tr>
<tr>
<td>Secondary Diagnosis 7</td>
<td>3792</td>
</tr>
<tr>
<td>Secondary Diagnosis 8</td>
<td>3794</td>
</tr>
<tr>
<td>Secondary Diagnosis 9</td>
<td>3796</td>
</tr>
<tr>
<td>Secondary Diagnosis 10</td>
<td>3798</td>
</tr>
</tbody>
</table>
### 12 Appendix C Revised Valid Values for AJCC T, N, and M

C.1 Revised look-up tables for use within Version 16.0 software and listing of added/deleted codes for AJCC T, N, and M data items

#### Table 1. TNM Clin T [940]

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>(blank)</td>
<td>Not recorded</td>
<td>c1B</td>
<td>cT1b</td>
<td>c3</td>
<td>cT3</td>
</tr>
<tr>
<td>cX</td>
<td>cTX</td>
<td>c1B1</td>
<td>cT1b1</td>
<td>c3A</td>
<td>cT3a</td>
</tr>
<tr>
<td>c0</td>
<td>cT0</td>
<td>c1B2</td>
<td>cT1b2</td>
<td>c3B</td>
<td>cT3b</td>
</tr>
<tr>
<td>pA</td>
<td>pTa</td>
<td>c1C</td>
<td>cT1c</td>
<td>c3C</td>
<td>cT3c</td>
</tr>
<tr>
<td>piS</td>
<td>pTis</td>
<td>c1D</td>
<td>cT1d</td>
<td>c3D</td>
<td>cT3d</td>
</tr>
<tr>
<td>piSU</td>
<td>pTispu</td>
<td>c2</td>
<td>cT2</td>
<td>c4</td>
<td>cT4</td>
</tr>
<tr>
<td>piSD</td>
<td>pTispd</td>
<td>c2A</td>
<td>cT2a</td>
<td>c4A</td>
<td>cT4a</td>
</tr>
<tr>
<td>c1MI</td>
<td>cT1mi, cT1 mic</td>
<td>c2A1</td>
<td>cT2a1</td>
<td>c4B</td>
<td>cT4b</td>
</tr>
<tr>
<td>c1</td>
<td>cT1</td>
<td>c2A2</td>
<td>cT2a2</td>
<td>c4C</td>
<td>cT4c</td>
</tr>
<tr>
<td>c1A</td>
<td>cT1a</td>
<td>c2B</td>
<td>cT2b</td>
<td>c4D</td>
<td>cT4d</td>
</tr>
<tr>
<td>c1A1</td>
<td>cT1a1</td>
<td>c2C</td>
<td>cT2c</td>
<td>c4E</td>
<td>cT4e</td>
</tr>
<tr>
<td>c1A2</td>
<td>cT1a2</td>
<td>c2D</td>
<td>cT2d</td>
<td>88</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

Deleted codes: A [Ta], IS [Tis], ISPU [Tispu], ISPD [Tispd]

Added codes: pA [pTa], piS [pTis], piSU [pTispu], piSD [pTispd]

#### Table 2. TNM Path T [880]

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>(blank)</td>
<td>Not recorded</td>
<td>p1B</td>
<td>pT1b</td>
<td>p3</td>
<td>pT3</td>
</tr>
<tr>
<td>pX</td>
<td>pTX</td>
<td>p1B1</td>
<td>pT1b1</td>
<td>p3A</td>
<td>pT3a</td>
</tr>
<tr>
<td>p0</td>
<td>pT0</td>
<td>p1B2</td>
<td>pT1b2</td>
<td>p3B</td>
<td>pT3b</td>
</tr>
<tr>
<td>pA</td>
<td>pTa</td>
<td>p1C</td>
<td>pT1c</td>
<td>p3C</td>
<td>pT3c</td>
</tr>
<tr>
<td>piS</td>
<td>pTis</td>
<td>p1D</td>
<td>pT1d</td>
<td>p3D</td>
<td>pT3d</td>
</tr>
<tr>
<td>piSU</td>
<td>pTispu</td>
<td>p2</td>
<td>pT2</td>
<td>p4</td>
<td>pT4</td>
</tr>
<tr>
<td>piSD</td>
<td>pTispd</td>
<td>p2A</td>
<td>pT2a</td>
<td>p4A</td>
<td>pT4a</td>
</tr>
<tr>
<td>p1MI</td>
<td>pT1mi, pT1 mic</td>
<td>p2A1</td>
<td>pT2a1</td>
<td>p4B</td>
<td>pT4b</td>
</tr>
<tr>
<td>p1</td>
<td>pT1</td>
<td>p2A2</td>
<td>pT2a2</td>
<td>p4C</td>
<td>pT4c</td>
</tr>
<tr>
<td>p1A</td>
<td>pT1a</td>
<td>p2B</td>
<td>pT2b</td>
<td>p4D</td>
<td>pT4d</td>
</tr>
<tr>
<td>p1A1</td>
<td>pT1a1</td>
<td>p2C</td>
<td>pT2c</td>
<td>p4E</td>
<td>pT4e</td>
</tr>
<tr>
<td>p1A2</td>
<td>pT1a2</td>
<td>p2D</td>
<td>pT2d</td>
<td>88</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

Added codes: piSU [pTispu], piSD [pTispd]

#### Table 3. TNM Clin N [950]

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>(blank)</td>
<td>Not recorded</td>
<td>c1B</td>
<td>cN1b</td>
<td>c3A</td>
<td>cN3a</td>
</tr>
<tr>
<td>cX</td>
<td>cNX</td>
<td>c1C</td>
<td>cN1c</td>
<td>c3B</td>
<td>cN3b</td>
</tr>
<tr>
<td>c0</td>
<td>cN0</td>
<td>c2</td>
<td>cN2</td>
<td>c3C</td>
<td>cN3c</td>
</tr>
<tr>
<td>c0A</td>
<td>cN0a</td>
<td>c2A</td>
<td>cN2a</td>
<td>c4</td>
<td>cN4</td>
</tr>
<tr>
<td>c0B</td>
<td>cN0b</td>
<td>c2B</td>
<td>cN2b</td>
<td>88</td>
<td>Not applicable</td>
</tr>
<tr>
<td>c1</td>
<td>cN1</td>
<td>c2C</td>
<td>cN2c</td>
<td>c3</td>
<td>cN3</td>
</tr>
<tr>
<td>c1A</td>
<td>cNa</td>
<td>c3</td>
<td>cN3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Deleted codes: c0l- [cNOI-], c0l+ [cNOI+], c0M- [cNOM-], c0M+ [cNOM+], c1MI [cN1mi] (used for pathologic staging only)
### Table 4. TNM Path N [890]

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>(blank)</td>
<td>Not recorded</td>
<td>p0A</td>
<td>pN0a</td>
<td>p2C</td>
<td>pN2c</td>
</tr>
<tr>
<td>pX</td>
<td>pNX</td>
<td>p0B</td>
<td>pN0b</td>
<td>p3</td>
<td>pN3</td>
</tr>
<tr>
<td>c0</td>
<td>cN0</td>
<td>p1</td>
<td>pN1</td>
<td>p3A</td>
<td>pN3a</td>
</tr>
<tr>
<td>p0</td>
<td>pN0</td>
<td>p1A</td>
<td>pN1a</td>
<td>p3B</td>
<td>pN3b</td>
</tr>
<tr>
<td>p0I-</td>
<td>pN0i-</td>
<td>p1B</td>
<td>pN1b</td>
<td>p3C</td>
<td>pN3c</td>
</tr>
<tr>
<td>p0I+</td>
<td>pN0i+</td>
<td>p1C</td>
<td>pN1c</td>
<td>p4</td>
<td>pN4</td>
</tr>
<tr>
<td>p0M-</td>
<td>pN0m-</td>
<td>p2</td>
<td>pN2</td>
<td>88</td>
<td>Not applicable</td>
</tr>
<tr>
<td>p0M+</td>
<td>pN0m+</td>
<td>p2A</td>
<td>pN2a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p1M</td>
<td>pN1m</td>
<td>p2B</td>
<td>pN2b</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Added code: of c0 [cN0] (In 2016, this new category is to be used for in situ only; use of this category will be expanded for the AJCC 8th Edition).

### Table 5. TNM Clin M [960]

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>(blank)</td>
<td>Not recorded</td>
<td>p1</td>
<td>pM1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c0</td>
<td>cM0</td>
<td>p1A</td>
<td>pM1a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c0I+</td>
<td>cM0(I+)</td>
<td>p1B</td>
<td>pM1b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c1</td>
<td>cM1</td>
<td>p1C</td>
<td>pM1c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c1A</td>
<td>cM1a</td>
<td>p1D</td>
<td>pM1d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c1B</td>
<td>cM1b</td>
<td>p1E</td>
<td>pM1e</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c1C</td>
<td>cM1c</td>
<td>88</td>
<td>Not applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c1D</td>
<td>cM1d</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c1E</td>
<td>cM1e</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Added codes: p1, p1A, p1B, p1C, p1D, and p1E [pM1, pM1a, pM1b, pM1c, pM1d, pM1e, respectively]

### Table 6. TNM Path M [900]

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>(blank)</td>
<td>Not recorded</td>
<td>p1C</td>
<td>pM1c</td>
<td>c1C</td>
<td>cM1c</td>
</tr>
<tr>
<td>c0</td>
<td>cM0</td>
<td>p1D</td>
<td>pM1d</td>
<td>c1D</td>
<td>cM1d</td>
</tr>
<tr>
<td>c0I+</td>
<td>cM0(I+)</td>
<td>p1E</td>
<td>pM1e</td>
<td>c1E</td>
<td>cM1e</td>
</tr>
<tr>
<td>p1</td>
<td>pM1</td>
<td>c1</td>
<td>cM1</td>
<td>88</td>
<td>Not applicable</td>
</tr>
<tr>
<td>p1A</td>
<td>pM1a</td>
<td>c1A</td>
<td>cM1a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p1B</td>
<td>pM1b</td>
<td>c1B</td>
<td>cM1b</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Deleted code: 0 [M0]

Added codes: c0 [cM0], c0I+ [cM0(I+)], c1 [cM1], c1A, c1B, C1C, C1D, and C1E [cM1a, cM1b, cM1c, cM1d, cM1e, respectively]
C.2 Conversion Specifications for AJCC T, N, and M data items [940, 950, 960, 880, 890, and 900] for Historical Data

1. Add prefix “c” to any existing clinical T (except A, IS, ISPU, ISPD, SU, SD)
2. Add prefix “c” to any existing clinical N and M value
3. Do not prefix blank or 88
4. Add prefix “p” to any existing pathologic T (except ISPU, ISPD, SU, SD)
5. Add prefix “p” to any existing pathologic N and M value
6. Do not prefix blank or 88
7. For clinical T:
   a. Revise the following values:
      ii. IS [Tis] to pIS [pTis]
      iii. ISPU [Tispu] to pISU [pTisu]
      iv.  ISPD [Tispd] to pISD [pTisd]
      v.  SU [Tsu] to pISU [pTisu]
      vi.  SD [Tsd] to pISD [pTisd]

8. For pathologic T:
   a. Revise the following values:
      i.  ISPU [Tispu] to pISU [pTisu]
      ii. ISPD [Tispd] to pISD [pTisd]
      iii. SU [Tsu] to pISU [pTisu]
      iv.  SD [Tsd] to pISD [pTisd]

SU and SD were valid for 5th and 6th editions of AJCC.
### 13 Appendix D ICD-O-3 Histology Code Crosswalk

**Continued Use of ICD-O-3 Histology Code Crosswalk:**

The following table is an excerpt from the NAACCR Guidelines for ICD-O-3 Update Implementation (December 2013). The complete document can be found on the NAACCR web site: Guidelines for ICD-O-3 Update Implementation

<table>
<thead>
<tr>
<th>ICD-O-3 Change</th>
<th>ICD-O-3 Histology Code (do NOT use these codes)</th>
<th>Description</th>
<th>Comment</th>
<th>Use this Histology Code in 2015 and 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>New term and code</td>
<td>8158/1</td>
<td>Endocrine tumor, functioning, NOS</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New related term</td>
<td>8158/1</td>
<td>ACTH-producing tumor</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New term and code</td>
<td>8163/3</td>
<td>Pancreatobiliary-type carcinoma (C24.1)</td>
<td>DO NOT use new code</td>
<td>8255/3</td>
</tr>
<tr>
<td>New synonym</td>
<td>8163/3</td>
<td>Adenocarcinoma, pancreatobiliary-type (C24.1)</td>
<td>DO NOT use new code</td>
<td>8255/3</td>
</tr>
<tr>
<td>New term</td>
<td>8213/3</td>
<td>Serrated adenocarcinoma</td>
<td></td>
<td>8213/3*</td>
</tr>
<tr>
<td>New code and term</td>
<td>8265/3</td>
<td>Micropapillary carcinoma, NOS (C18., C19.9, C20.9)</td>
<td>DO NOT use new code</td>
<td>8507/3*</td>
</tr>
<tr>
<td>New code and term</td>
<td>8480/1</td>
<td>Low grade appendiceal mucinous neoplasm (C18.1)</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New term and code</td>
<td>8552/3</td>
<td>Mixed acinar ductal carcinoma</td>
<td>DO NOT use new code</td>
<td>8523/3</td>
</tr>
<tr>
<td>New term and code</td>
<td>8975/1</td>
<td>Calcifying nested epithelial stromal tumor (C22.0)</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New term and code</td>
<td>9395/3</td>
<td>Papillary tumor of the pineal region</td>
<td>DO NOT use new code</td>
<td>9361/3*</td>
</tr>
<tr>
<td>ICD-O-3 Change</td>
<td>ICD-O-3 Histology Code (do NOT use these codes)</td>
<td>Description</td>
<td>Comment</td>
<td>Use this Histology Code in 2015 and 2016</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>New term and code</td>
<td>9425/3</td>
<td>Pilomyxoid astrocytoma</td>
<td>DO NOT use new code</td>
<td>9421/3</td>
</tr>
<tr>
<td>New term and code</td>
<td>9431/1</td>
<td>Angiocentric glioma</td>
<td>DO NOT use new code</td>
<td>9380/1*</td>
</tr>
<tr>
<td>New term and code</td>
<td>9432/1</td>
<td>Pituicytoma</td>
<td>DO NOT use new code</td>
<td>9380/1*</td>
</tr>
<tr>
<td>New term and code</td>
<td>9509/1</td>
<td>Papillary glioneuronal tumor</td>
<td>DO NOT use new code</td>
<td>9505/1</td>
</tr>
<tr>
<td>New related term</td>
<td>9509/1</td>
<td>Rosette-forming glioneuronal tumor</td>
<td>DO NOT use new code</td>
<td>9505/1</td>
</tr>
<tr>
<td>New term and code</td>
<td>9741/1</td>
<td>Indolent systemic mastocytosis</td>
<td>Not reportable</td>
<td></td>
</tr>
</tbody>
</table>

* ICD-O-3 rule F applies (code the behavior stated by the pathologist). If necessary, over-ride any advisory messages.
## Appendix E CDC NPCR Changes to 2016 Required Status Table

<table>
<thead>
<tr>
<th>Item</th>
<th>Item Name</th>
<th>Status</th>
<th>Change(s)</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>94</td>
<td>Census County 1990</td>
<td>D</td>
<td>New</td>
<td>Populated through the geocoding process to ensure appropriate county for the decennial Census used to assign Census Tract.</td>
</tr>
<tr>
<td>95</td>
<td>Census County 2000</td>
<td>D</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>Census County 2010</td>
<td>D</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>756</td>
<td>Tumor Size Summary</td>
<td>R</td>
<td>New</td>
<td>Captures a single best tumor size from all information available.</td>
</tr>
<tr>
<td>3312</td>
<td>Rural Urban Continuum 2013</td>
<td>D</td>
<td>New</td>
<td>Codes can be derived electronically, using patients’ state and county at diagnosis.</td>
</tr>
<tr>
<td>3650</td>
<td>NPCR Derived Clin Stg Grp</td>
<td>R</td>
<td>New</td>
<td>Central Registry Only: Intended to capture stage group derived from AJCC-TNM tables and assist central registries post-consolidation.</td>
</tr>
<tr>
<td>3655</td>
<td>NPCR Derived Path Stg Grp</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>880</td>
<td>TNM Path T</td>
<td>R</td>
<td>RN to R</td>
<td>Transition from CSv2 to directly-assigned AJCC-TNM. Required from ALL facilities.</td>
</tr>
<tr>
<td>890</td>
<td>TNM Path N</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>900</td>
<td>TNM Path M</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>910</td>
<td>TNM Path Stage Group</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>920</td>
<td>TNM Path Descriptor</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>940</td>
<td>TNM Clin T</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>950</td>
<td>TNM Clin N</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>960</td>
<td>TNM Clin M</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>970</td>
<td>TNM Clin Stage Group</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>980</td>
<td>TNM Clin Descriptor</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>1060</td>
<td>TNM Edition Number</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>1380</td>
<td>RX Summ - Surg/Rad Seq</td>
<td>R</td>
<td>RN to R</td>
<td>Helpful in assessing neoadjuvant therapy. Required from ALL facilities.</td>
</tr>
<tr>
<td>1639</td>
<td>RX Summ – Systemic/Sur Seq</td>
<td>R</td>
<td>RN to R</td>
<td></td>
</tr>
<tr>
<td>2861</td>
<td>CS SSF7</td>
<td>RH</td>
<td>RS* to RH</td>
<td>No longer needed for 2016+</td>
</tr>
<tr>
<td>2864</td>
<td>CS SSF10</td>
<td>RS</td>
<td>RS* to RS</td>
<td>See Table 2 below</td>
</tr>
<tr>
<td>2866</td>
<td>CS SSF12</td>
<td>RH</td>
<td>RS* to RH</td>
<td>No longer needed for 2016+</td>
</tr>
<tr>
<td>2871</td>
<td>CS SSF17</td>
<td>RH</td>
<td>RS* to RH</td>
<td>No longer needed for 2016+</td>
</tr>
<tr>
<td>2872-2878</td>
<td>Site Specific Factors 18-24</td>
<td>Blank/Not Required</td>
<td>RS* to Blank</td>
<td>These data items were never used to calculate Derived Summary Stage 2000 or Derived AJCC-TNM Stage and were never prognostic factors of interest.</td>
</tr>
<tr>
<td>2900</td>
<td>CS SSF3</td>
<td>RH</td>
<td>RS to RH</td>
<td>No longer needed for 2016+</td>
</tr>
<tr>
<td>2910</td>
<td>CS SSF4</td>
<td>RH</td>
<td>RS* to RH</td>
<td>No longer needed for 2016+</td>
</tr>
<tr>
<td>2920</td>
<td>CS SSF5</td>
<td>RS</td>
<td>RS* to RS</td>
<td>See Table 2 below</td>
</tr>
<tr>
<td>2930</td>
<td>CS SSF6</td>
<td>RS</td>
<td>RS* to RS</td>
<td>See Table 2 below</td>
</tr>
<tr>
<td>2800</td>
<td>CS Tumor Size</td>
<td>RH</td>
<td>R to RH</td>
<td></td>
</tr>
<tr>
<td>2810</td>
<td>CS Extension</td>
<td>RH</td>
<td>R to RH</td>
<td></td>
</tr>
</tbody>
</table>
### CDC NPCR 2016 Requirements

<table>
<thead>
<tr>
<th>Item</th>
<th>Item Name</th>
<th>Status</th>
<th>Change(s)</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>2820</td>
<td>CS Tumor Size/Ext Eval</td>
<td>RH</td>
<td>R to RH</td>
<td>These data items are required historically for deriving SEER Summary Stage for cases diagnosed 2004-2015.</td>
</tr>
<tr>
<td>2830</td>
<td>CS Lymph Nodes</td>
<td>RH</td>
<td>R to RH</td>
<td></td>
</tr>
<tr>
<td>2850</td>
<td>CS Mets at DX</td>
<td>RH</td>
<td>R to RH</td>
<td></td>
</tr>
<tr>
<td>2936</td>
<td>CS Version Derived</td>
<td>RH</td>
<td>R to RH</td>
<td></td>
</tr>
<tr>
<td>3020</td>
<td>Derived SS2000</td>
<td>RH</td>
<td>R to RH</td>
<td></td>
</tr>
<tr>
<td>3050</td>
<td>Derived SS2000--Flag</td>
<td>RH</td>
<td>R to RH</td>
<td></td>
</tr>
<tr>
<td>2840</td>
<td>CS Lymph Nodes Eval</td>
<td>RH*</td>
<td>R* to RH*</td>
<td>These data items are required historically, as available, for deriving AJCC TNM Stage for cases diagnosed 2011-2015.</td>
</tr>
<tr>
<td>2860</td>
<td>CS Mets Eval</td>
<td>RH*</td>
<td>R* to RH*</td>
<td></td>
</tr>
<tr>
<td>3400</td>
<td>Derived AJCC-7 T</td>
<td>RH*</td>
<td>D* to RH*</td>
<td></td>
</tr>
<tr>
<td>3402</td>
<td>Derived AJCC-7 T Descript</td>
<td>RH*</td>
<td>D* to RH*</td>
<td></td>
</tr>
<tr>
<td>3410</td>
<td>Derived AJCC-7 N</td>
<td>RH*</td>
<td>D* to RH*</td>
<td></td>
</tr>
<tr>
<td>3412</td>
<td>Derived AJCC-7 N Descript</td>
<td>RH*</td>
<td>D* to RH*</td>
<td></td>
</tr>
<tr>
<td>3420</td>
<td>Derived AJCC-7 M</td>
<td>RH*</td>
<td>D* to RH*</td>
<td></td>
</tr>
<tr>
<td>3422</td>
<td>Derived AJCC-7 M Descript</td>
<td>RH*</td>
<td>D* to RH*</td>
<td></td>
</tr>
<tr>
<td>3430</td>
<td>Derived AJCC-7 Stage Grp</td>
<td>RH*</td>
<td>D* to RH*</td>
<td></td>
</tr>
<tr>
<td>3750-</td>
<td>Over-ride CS 1-19</td>
<td>Blank/Not Required</td>
<td>R to Blank</td>
<td>These data items were never defined or used for data collection.</td>
</tr>
<tr>
<td>3768</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3769</td>
<td>Over-ride CS 20</td>
<td>RH</td>
<td>R to RH</td>
<td>Required historically for cases that were assigned directly coded SS00 in lieu of CS derived SS due to resource limitations.</td>
</tr>
</tbody>
</table>

R = REQUIRED; R* = REQUIRED, WHEN AVAILABLE; RS = REQUIRED, SITE-SPECIFIC; RS* REQUIRED, SITE-SPECIFIC, WHEN AVAILABLE; D* = DERIVED, SITE-SPECIFIC; RN = IMPLEMENT ACCORDING TO NPCR STAGE TRANSITION PLAN; RH = REQUIRED HISTORICALLY; RH* = REQUIRED HISTORICALLY, WHEN AVAILABLE
## Changes in NCI SEER Requirements for 2016

<table>
<thead>
<tr>
<th>Item #</th>
<th>Item Name</th>
<th>SEER Collect</th>
<th>SEER Transmit</th>
<th>Note</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>94</td>
<td>County at DX Geocode 1990</td>
<td>D</td>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>County at DX Geocode 2000</td>
<td>D</td>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>County at DX Geocode 2010</td>
<td>D</td>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>County at DX Geocode 2020</td>
<td>D</td>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>752</td>
<td>Tumor Size Clinical</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>754</td>
<td>Tumor Size Pathologic</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>756</td>
<td>Tumor Size Summary</td>
<td>S</td>
<td>S</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>759</td>
<td>SEER Summary Stage 2000</td>
<td>R+</td>
<td>R+</td>
<td>Revised</td>
<td>Required, either directly-assigned (759) or derived from CS (3020)</td>
</tr>
<tr>
<td>762</td>
<td>Derived SS2017</td>
<td>.</td>
<td>.</td>
<td>New</td>
<td>Not required for 2016 cases</td>
</tr>
<tr>
<td>764</td>
<td>Directly Assigned SS2017</td>
<td>.</td>
<td>.</td>
<td>New</td>
<td>Not required for 2016 cases</td>
</tr>
<tr>
<td>772</td>
<td>SEER Primary Tumor</td>
<td>.</td>
<td>.</td>
<td>New</td>
<td>Not required for 2016 cases</td>
</tr>
<tr>
<td>774</td>
<td>SEER Regional Nodes</td>
<td>.</td>
<td>.</td>
<td>New</td>
<td>Not required for 2016 cases</td>
</tr>
<tr>
<td>776</td>
<td>SEER Mets</td>
<td>.</td>
<td>.</td>
<td>New</td>
<td>Not required for 2016 cases</td>
</tr>
<tr>
<td>880</td>
<td>TNM Path T</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>890</td>
<td>TNM Path N</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>900</td>
<td>TNM Path M</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>910</td>
<td>TNM Path Stage Group</td>
<td>S</td>
<td>S</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>920</td>
<td>TNM Path Descriptor</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>930</td>
<td>TNM Path Staged By</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>940</td>
<td>TNM Clin T</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>950</td>
<td>TNM Clin N</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>960</td>
<td>TNM Clin M</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>970</td>
<td>TNM Clin Stage Group</td>
<td>S</td>
<td>S</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>980</td>
<td>TNM Clin Descriptor</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>990</td>
<td>TNM Clin Staged By</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>1060</td>
<td>TNM Edition Number</td>
<td>R</td>
<td>R</td>
<td>Revised</td>
<td></td>
</tr>
<tr>
<td>1112</td>
<td>Mets at DX–Bone</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1113</td>
<td>Mets at DX–Brain</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1114</td>
<td>Mets at DX–Distant LN</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1115</td>
<td>Mets at DX–Liver</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1116</td>
<td>Mets at DX–Lung</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1117</td>
<td>Mets at DX–Other</td>
<td>R</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1320</td>
<td>RX Summ--Surgical Margins</td>
<td>R*</td>
<td>R*</td>
<td></td>
<td>Required when available</td>
</tr>
<tr>
<td>1782</td>
<td>Surv-Date Active Followup</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>Item #</td>
<td>Item Name</td>
<td>SEER Collect</td>
<td>SEER Transmit</td>
<td>Note</td>
<td>Rationale</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------------------</td>
<td>--------------</td>
<td>---------------</td>
<td>-------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>1783</td>
<td>Surv-Flag Active Followup</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1784</td>
<td>Surv-Mos Active Followup</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1785</td>
<td>Surv-Date Presumed Alive</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1786</td>
<td>Surv-Flag Presumed Alive</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1787</td>
<td>Surv-Mos Presumed Alive</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1788</td>
<td>Surv-Date DX Recode</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>1942</td>
<td>Place of Death--State</td>
<td>R*</td>
<td>R*</td>
<td></td>
<td>Required when available</td>
</tr>
<tr>
<td>1944</td>
<td>Place of Death--Country</td>
<td>R*</td>
<td>R*</td>
<td></td>
<td>Required when available</td>
</tr>
<tr>
<td>1981</td>
<td>Over-ride SS/NodesPos</td>
<td>R</td>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>Over-ride SS/TNM-N</td>
<td>R</td>
<td>R</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983</td>
<td>Over-ride SS/TNM-M</td>
<td>R</td>
<td>R</td>
<td></td>
<td>Required to collect when available</td>
</tr>
<tr>
<td>2355</td>
<td>Addr Current--Supplementl</td>
<td>R*</td>
<td></td>
<td></td>
<td>Required to collect when available</td>
</tr>
<tr>
<td>2440</td>
<td>Following Registry</td>
<td>RH</td>
<td></td>
<td></td>
<td>No longer required for 2016 cases</td>
</tr>
<tr>
<td>2445</td>
<td>NPI--Following Registry</td>
<td>RH*</td>
<td></td>
<td></td>
<td>No longer required for 2016 cases</td>
</tr>
<tr>
<td>2800</td>
<td>CS Tumor Size</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2810</td>
<td>CS Extension</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2820</td>
<td>CS Tumor Size/Ext Eval</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2830</td>
<td>CS Lymph Nodes</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2840</td>
<td>CS Lymph Nodes Eval</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2850</td>
<td>CS Mets at DX</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2851</td>
<td>CS Mets at Dx-Bone</td>
<td>RH</td>
<td>RH</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2852</td>
<td>CS Mets at Dx-Brain</td>
<td>RH</td>
<td>RH</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2853</td>
<td>CS Mets at Dx-Liver</td>
<td>RH</td>
<td>RH</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2854</td>
<td>CS Mets at Dx-Lung</td>
<td>RH</td>
<td>RH</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2860</td>
<td>CS Mets Eval</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2935</td>
<td>CS Version Input Original</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2936</td>
<td>CS Version Derived</td>
<td>D*</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2937</td>
<td>CS Version Input Current</td>
<td>S</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>Item #</td>
<td>Item Name</td>
<td>SEER Collect</td>
<td>SEER Transmit</td>
<td>Note</td>
<td>Rationale</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------</td>
<td>--------------</td>
<td>---------------</td>
<td>--------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2940</td>
<td>Derived AJCC-6 T</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2950</td>
<td>Derived AJCC-6 T Descript</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2960</td>
<td>Derived AJCC-6 N</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2970</td>
<td>Derived AJCC-6 N Descript</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2980</td>
<td>Derived AJCC-6 M</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>2990</td>
<td>Derived AJCC-6 M Descript</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3000</td>
<td>Derived AJCC-6 Stage Grp</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3010</td>
<td>Derived SS1977</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3020</td>
<td>Derived SS2000</td>
<td>D+</td>
<td>R+</td>
<td>Note</td>
<td>Required, either directly-assigned (759) or derived from CS (3020)</td>
</tr>
<tr>
<td>3030</td>
<td>Derived AJCC--Flag</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3040</td>
<td>Derived SS1977--Flag</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3050</td>
<td>Derived SS2000--Flag</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3230</td>
<td>RX Date Systemic</td>
<td>RC</td>
<td>RC</td>
<td>Note</td>
<td></td>
</tr>
<tr>
<td>3231</td>
<td>RX Date Systemic Flag</td>
<td>RC</td>
<td>RC</td>
<td>Note</td>
<td></td>
</tr>
<tr>
<td>3312</td>
<td>RuralUrban Continuum 2013</td>
<td>D</td>
<td>R</td>
<td>Note</td>
<td></td>
</tr>
<tr>
<td>3400</td>
<td>Derived AJCC-7 T</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3402</td>
<td>Derived AJCC-7 T Descript</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3410</td>
<td>Derived AJCC-7 N</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3412</td>
<td>Derived AJCC-7 N Descript</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3420</td>
<td>Derived AJCC-7 M</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3422</td>
<td>Derived AJCC-7 M Descript</td>
<td>D*</td>
<td>S</td>
<td>Note</td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
</tbody>
</table>
### Changes in NCI SEER Requirements for 2016

<table>
<thead>
<tr>
<th>Item #</th>
<th>Item Name</th>
<th>SEER Collect</th>
<th>SEER Transmit</th>
<th>Note</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>3430</td>
<td>Derived AJCC-7 Stage Grp</td>
<td>D*</td>
<td>S</td>
<td></td>
<td>Required for SEER registries collecting CS for 2016 cases</td>
</tr>
<tr>
<td>3605</td>
<td>Derived SEER Path Stg Grp</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3610</td>
<td>Derived SEER Clin Stg Grp</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3614</td>
<td>Derived SEER Cmb Stg Grp</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3616</td>
<td>Derived SEER Combined T</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3618</td>
<td>Derived SEER Combined N</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3620</td>
<td>Derived SEER Combined M</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3622</td>
<td>Derived SEER Cmb T Src</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3624</td>
<td>Derived SEER Cmb N Src</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
<tr>
<td>3626</td>
<td>Derived SEER Cmb M Src</td>
<td>D</td>
<td>R</td>
<td>New</td>
<td></td>
</tr>
</tbody>
</table>

R = Required; R* = Required, when available; RC = Collected by SEER from CoC-accredited hospitals; R+ = Required, central registries may collect either seer summary stage 2000 or collaborative stage; RH = Historically collected and currently transmitted; RH* = Historically collected and currently transmitted when available; D = Derived; D* = Derived, when available; D+ = Derived, central registries may collect either seer summary stage 2000 or collaborative stage; S = Supplementary/recommended
## Appendix G Revision Control

<table>
<thead>
<tr>
<th>Version Number</th>
<th>Revision Date</th>
<th>Section</th>
<th>Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>12/4/15</td>
<td>Cover page</td>
<td>Added version number and added Revised December 2015.</td>
</tr>
<tr>
<td>1.1</td>
<td>12/4/15</td>
<td>4.2</td>
<td>In the second paragraph, added the last sentence.</td>
</tr>
<tr>
<td>1.1</td>
<td>12/4/15</td>
<td>4.2</td>
<td>Deleted the Note at the end of this section.</td>
</tr>
<tr>
<td>1.1</td>
<td>12/4/15</td>
<td>6.1</td>
<td>Added, Implementation of Clinical and Pathologic Indicators for the AJCC T, N, and M Data Items and the following two paragraphs.</td>
</tr>
<tr>
<td>1.1</td>
<td>12/4/15</td>
<td>6.2</td>
<td>Added paragraph above the Required Site-Specific Factors regarding CDC NPCR implementation of clinical and pathologic indicators for the AJCC T, N, and M data items.</td>
</tr>
<tr>
<td>1.1</td>
<td>12/4/15</td>
<td>6.3</td>
<td>Added second paragraph regarding NCI SEER implementation of clinical and pathologic indicators for the AJCC T, N, and M data items.</td>
</tr>
<tr>
<td>1.1</td>
<td>12/4/15</td>
<td>Appendix C</td>
<td>Deleted the Notes, added table numbers, added the deleted codes and the added codes following each table, and revised C.2.</td>
</tr>
<tr>
<td>1.2</td>
<td>12/21/15</td>
<td>Appendix C</td>
<td>In C.1. added note after Table 3 and modified note after Table 4. In C.2. in 1 and 2 added SU and SD, and “do not prefix blank or 88”; added 3.a.v and 3.a.vi.; added 4.a.iii. and 4.a.iv.; and, added the last sentence regarding SU and SD.</td>
</tr>
<tr>
<td>1.3</td>
<td>1/12/16</td>
<td>Appendix C</td>
<td>Changed codes/definitions in Table 3 and Table 6 to be consistent with changes made in the 2016 IG Version 1.2 and the notes below each of the tables.</td>
</tr>
<tr>
<td>1.3</td>
<td>1/12/16</td>
<td>6.2</td>
<td>In Table 1 for Prostate added SSF 8 and 10, and added Gleason Score to Description.</td>
</tr>
<tr>
<td>1.4</td>
<td>3/28/16</td>
<td>4.2</td>
<td>Replaced 1st paragraph and added 3 new paragraphs at the beginning of this section.</td>
</tr>
<tr>
<td>1.4</td>
<td>3/28/16</td>
<td>4.2.1</td>
<td>Added section 4.2.1.</td>
</tr>
<tr>
<td>1.4</td>
<td>3/28/16</td>
<td>5</td>
<td>In the second paragraph, changed the Version 16 metafile release date from February 2016 to spring 2016.</td>
</tr>
<tr>
<td>1.4</td>
<td>3/28/16</td>
<td>6.3</td>
<td>Added table, SEER SSFs No Longer Applicable. Updated last paragraph by replacing ‘Staging and Predictive and Prognostic (S&amp;PP) factors data warehouse’ with ‘SEER Registrar Staging Assistant (SEER*RSA)’.</td>
</tr>
<tr>
<td>1.4</td>
<td>3/28/16</td>
<td>9.5</td>
<td>Added Northcon Conversion Utility paragraph.</td>
</tr>
<tr>
<td>1.4</td>
<td>3/28/16</td>
<td>Appendix A</td>
<td>The following sentences was added to the first paragraph: The conversion below will be performed across all diagnosis</td>
</tr>
<tr>
<td>Date</td>
<td>Change</td>
<td>Appendix</td>
<td>Notes</td>
</tr>
<tr>
<td>------------</td>
<td>---------</td>
<td>----------</td>
<td>-------</td>
</tr>
</tbody>
</table>
| 3/28/16    | Appendix C | The following was added to C.1: **for use within Version 16.0 software.** The following was revised in C.2:
|            |         |          | 1. Add prefix “c” to any existing clinical T (except A, IS, ISPU, ISPD, SU, SD)
|            |         |          | 2. Add prefix “c” to any existing clinical N and M value
|            |         |          | 3. Do not prefix blank or 88
|            |         |          | 4. Add prefix “p” to any existing pathologic T (except ISPU, ISPD, SU, SD)
|            |         |          | 5. Add prefix “p” to any existing pathologic N and M value
|            |         |          | 6. Do not prefix blank or 88 |
| 3/28/16    | Appendix H | Added Appendix H. |
| 6/21/16    | 5       | In 2nd paragraph, updated the release date. Updated the last three paragraphs. |
17 Appendix H TNM Classification Designator Impact (CDI):
Considerations for Central Registries

NAACCR TNM CDI Task Force Members: Colleen Sherman (NY), Jenna Mazreku (CA), Julia Espinoza (WY), Steven Peace (FL), Vicki Moxley (WY), Winny Roshala (CA), Jim Hofferkamp (NAACCR)

Directive/Charge to this Task Force
To identify issues central registries need to consider as they decide how to best operationalize receiving directly-assigned pre-2016 TNM data from reporting facilities, based on the implementation of the TNM c and p classification designators (TNM c and p “prefixes” or “indicators”). This would include both converted and non-converted directly-assigned pre-2016 TNM data.

Below are several issues and options central registries should consider when determining how to manage receiving converted directly-assigned pre-2016 TNM data, incorporating the c and p designators, as well as managing non-converted directly-assigned pre-2016 TNM data, without the c and p designators from reporting facilities.

Background Information and Reminders
1. Depending on central registry requirements, central registries may receive both converted and non-converted directly-assigned pre-2016 TNM data from reporting facilities.
2. Registries will continue to use Collaborative Stage for their stage data for cases diagnosed from 2004 through 2015.
3. Beginning with cases diagnosed in 2016, directly-assigned AJCC TNM and Summary Stage will be the primary source for stage data. Most registries will no longer collect Collaborative Stage data beginning with cases diagnosed in 2016, except for the SSFs.
4. The conversion of pre-2016 TNM data to include the classification designators only pertains to directly-assigned TNM values during this time period. The conversion does not impact or apply to TNM values derived from Collaborative Stage.
5. With the exception of requiring central registries to collect 2015 directly-assigned TNM data from CoC approved reporting facilities when available, the CDC’s NPCR and SEER do not require central registries collect directly-assigned pre-2016 TNM data. As such, the quality and accuracy of this data has not been assessed by most central registries.
6. The CDC’s NPCR and SEER are not requiring central registries to convert directly-assigned pre-2016 TNM data to include the c and p designators.
7. For SEER registries, the November 2016 data submission requires the inclusion of directly-assigned 2015 TNM data from CoC approved facilities when available, however, TNM data is not required to be converted to the 2016 standard to include the c and p designators.
8. The Northcon Conversion Utility will provide central registries with the option to convert or not convert directly-assigned pre-2016 TNM data.
   • The Northcon Conversion Utility only converts v15 files to v16. The utility cannot be used to add c and p designators to a file already in the v16 layout at the time this document was produced.
   • If the central registry selects the “Convert TNM Clin/Path Items,” c and p designators will be added to all of the directly-assigned pre-2016 TNM data items on their database.
If any 2016 cases are on the database prior to conversion, the c and p designators will have to be added manually.

- If the central registry does not select the “Convert TNM Clin/Path Items,” the conversion will occur without adding the c and p designators to directly-assigned pre-2016 TNM data items.
- CDC’s NPCR is developing a separate utility that can be used by central registries to remove the c and p designators from pre-2016 cases submitted by reporting facilities. Central registries that choose this option will need to run all incoming submissions through this utility for as long as pre-2016 cases are submitted.

9. The conversion specifications for directly-assigned pre-2016 TNM data items are included in Appendix C of the NAACCR 2016 Implementation Guidelines and Recommendations.

10. The TNM c and p designators are required by the CoC, CDC’s NPCR and SEER for all cases diagnosed 2016 forward.

11. Edit sets have been developed to accommodate each of the following scenarios for directly-assigned pre-2016 TNM data items:
   a. C and p designators are required
   b. C and p designators are not allowed
   c. TNM values are allowed with or without the c and p designators

Central registries will select which edits to include in their state metafile based on how they choose to accept incoming pre-2016 cases. See options 1-3 below.

12. For cases diagnosed prior to 2016, but seen at the reporting facility with recurrent or persistent disease in or after 2016:
   a. The CoC requires CoC approved reporting facilities to directly-assign TNM using the new designators, regardless of diagnosis date, once they have converted to v16 software. This applies to any case abstracted using v16 software.
   b. The CDC’s NPCR does not have a position on how grantees should handle TNM data with c and p designators for cases diagnosed before 2016, regardless of the software version used. NPCR is not requiring state registries to submit directly-assigned TNM data collected for diagnosis years prior to 2016, therefore they have not established any standards for such data.
   c. According to SEER, they allow, but do not require, c or p designators on pre-2016 diagnosed cases submitted 2016 or later.

13. For cases diagnosed in 2016, but first entered in v15 software, the T, N, and M values will not be converted and thus must be reviewed and manually assign the c and p designators.

Central registries will first have to decide what to do with directly-assigned TNM data for cases diagnosed prior to 2016 currently on their database. Registries will need to either keep the directly-assigned pre-2016 TNM data without the designators or convert it to include the designators. Consideration should be given to maintaining central registry data uniformity and consistency, as well as the impact of researcher use of the data. In addition, central registries will need to consider how to process incoming directly-assigned pre-2016 TNM data.

Options to Consider

Option #1:
Convert all directly-assigned pre-2016 TNM data in the central registry to include the TNM c and p designators.
a. Pros: Ease in accepting converted pre-2016 cases from reporting facilities, consistency with legacy data from CoC approved reporting facilities; moving forward to 2017, c and p designators are being formally written into the AJCC 8th edition. As a result, any registry that does not convert directly-assigned pre-2016 TNM data will eventually lack data uniformity for earlier years.

b. Cons: Potential negative impact in converting data not previously required to be collected by the CDC’s NPCR or SEER; converting data not previously assessed for accuracy or quality; implied accuracy of classification regarding TNM data.

c. Process incoming directly-assigned pre-2016 TNM data: Require all reporting facilities to directly assign TNM values with the c and p designators. At the time this document was produced, a utility to add the c and p designators to v16 cases had not been developed.

Option #2:
Do not convert directly-assigned pre-2016 TNM data in the central registry database and identify methods to disallow converted directly-assigned pre-2016 TNM data into the central registry database

a. Pros: No conversion work effort for the central registry; data remains consistent as is, without implied accuracy of classification regarding TNM data not previously required by the CDC’s NPCR or SEER.

b. Cons: Need to develop a method to disallow the c and p designators for directly-assigned pre-2016 TNM converted data; no legacy data with c and p designators leading to a lack of uniformity moving forward to 2017 data.

c. Process incoming directly-assigned pre-2016 TNM data: Allow reporting facilities to submit with or without the c and p designators. If cases are received with the c and p designators, the CDC’s NPCR utility currently under development, can be used to remove the designators prior to uploading the data to the central registry database.

Option #3:
Allow a “mixed bag” approach, so that central registries are able to accept cases with converted directly-assigned pre-2016 TNM data as well as cases without converted directly-assigned pre-2016 TNM data; the central registry could link the records and choose whether or not to consolidate the TNM stage data

a. Pros: Allows for flexibility and agility in dealing with receiving both converted and non-converted directly-assigned pre-2016 TNM data; data exchange files can be handled accordingly; edits can be selected as needed to accommodate the TNM format within the data file.

b. Cons: Lack of TNM data uniformity within the central registry data base; potential negative impact on data analysis, due to having a “mixed bag” of directly-assigned pre-2016 TNM data, difficulty in consolidating data from multiple facilities if the values from different facilities are not standardized.

c. Process incoming directly-assigned pre-2016 TNM data: Allow reporting facilities to submit with or without the c and p designators. The directly-assigned TNM data values will not be modified and will be added to the central registry database as submitted by the reporting facility.